Deafness-Dystonia-Optic Neuronopathy Syndrome

Genetic MONDO:0010578 Pathograph 21 Show in embeddings browser Mitochondrial Disease Inherited Neurodegenerative Disorder X-Linked Disorder

Deafness-dystonia-optic neuronopathy (DDON) syndrome, universally known in the clinical literature as Mohr-Tranebjaerg syndrome, is an X-linked recessive neurodegenerative disorder caused by loss of function of TIMM8A, which encodes the 97-amino-acid deafness/dystonia peptide DDP1 of the mitochondrial intermembrane space. Affected males follow a stereotyped four-stage sequence: prelingual or postlingual sensorineural hearing impairment in early childhood, slowly progressive dystonia or ataxia in the teens, decreased visual acuity from optic atrophy from about age 20, and dementia from about age 40. Psychiatric features do not belong to that last stage — personality change and paranoia may appear in childhood and progress alongside everything else. Two features distinguish this entry from a generic syndromic hearing-loss entry. First, the deafness is an auditory neuropathy: the lesion is retrocochlear, with near-total loss of cochlear spiral ganglion neurons on temporal-bone histopathology while the cochlear hair cells are comparatively spared. That is not a descriptive detail — it is why hearing aids and cochlear implantation have only variable success, and it makes the treatment section a consequence of the pathograph rather than a separate list. Second, the disorder was among the first framed as a mitochondrial disease of the protein-import machinery rather than of an oxidative-phosphorylation subunit: DDP1 partners with TIMM13 as a hexameric intermembrane-space chaperone that escorts hydrophobic precursors, notably TIM23, to the inner membrane. How that molecular lesion becomes a neuron-selective disease is not settled. The TIM23-import account rests on human and yeast in-vitro and in-organello work, but the Timm8a1 mutant mouse shows hearing and cognitive impairment with abnormal mitochondrial structure and yet no detectable defect in Tim23 import or in oxidative-phosphorylation biogenesis, and a 2025 patient-iPSC study calls the cross-membrane transport mechanism in humans controversial while locating the neuronal defect in complex IV assembly and a downstream fall in CHCHD2. This entry curates both readings and records the mismatch rather than harmonizing them.

Ask OpenScientist

Ask a research question about Deafness-Dystonia-Optic Neuronopathy Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
7
Pathophys.
2
Histopath.
9
Phenotypes
1
Gaps
21
Pathograph
1
Genes
5
Medical Actions
2
Subtypes
4
Differentials
3
Models
1
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0010578 deafness dystonia syndrome
skos:exactMatch
👪

Inheritance

1
X-linked recessive HP:0001419
Hemizygous males are essentially fully penetrant for the classic phenotype. Heterozygous females may have mild hearing impairment and focal dystonia; this is attributed to skewed X-chromosome inactivation rather than to a discrete modifier locus.
X-linked recessive inheritance
Show evidence (2 references)
PMID:20301395 SUPPORT Other
"DDON syndrome is inherited in an X-linked manner."
GeneReviews states the mode of inheritance.
PMID:20301395 SUPPORT Other
"females who inherit the genetic alteration will be heterozygotes and may have mild hearing impairment and focal dystonia"
Establishes the carrier-female phenotype.
◆

Subtypes

2
Intragenic TIMM8A variant (isolated DDON syndrome)
Point mutations, frameshifts, and small indels confined to TIMM8A, producing DDON syndrome without immunodeficiency. Reported alleles include the structurally characterized C66W missense change, the initiation-codon variant p.Met1Leu, and frameshifts such as p.His21Argfs*11 and p.Gln75fs95*.
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"a male proband who has a hemizygous TIMM8A pathogenic variant (~50% of affected males)"
GeneReviews gives the share of cases due to intragenic variants.
Contiguous Xq22.1 deletion (with X-linked agammaglobulinemia when BTK is included)
Deletions at Xq22.1 removing TIMM8A together with neighbouring genes. Where the deletion extends into BTK, which lies telomeric to TIMM8A, the patient additionally has X-linked agammaglobulinemia and needs immunoglobulin replacement. The immunodeficiency is a consequence of the deletion size, not of TIMM8A loss, so it is curated here and not as a pathophysiology node.
Show evidence (4 references)
PMID:37325222 SUPPORT Human Clinical
"When the contiguous gene deletion includes BTK, located telomeric to TIMM8A, it additionally results in X-linked agammaglobulinemia"
States that the immunodeficiency arises from co-deletion of BTK rather than from TIMM8A loss.
PMID:20301395 SUPPORT Other
"a contiguous gene deletion of Xq22.1 involving TIMM8A (~50% of affected males and females)"
GeneReviews gives the share of cases due to contiguous deletion.
PMID:36056138 SUPPORT Human Clinical
"The contiguous gene deletions most commonly include the BTK gene (MIM: #300,300), which is located less than one kb downstream of TIMM8A, but larger deletions involving additional genes in the region have also been described"
Primary deletion-architecture source. The sub-kilobase distance between TIMM8A and BTK is why this subtype exists at all: the two genes are close enough that a deletion large enough to remove one usually removes the other.
+ 1 more reference
?

Discussions and Knowledge Gaps

1
Is impaired TIM23 import actually the operative lesion, given that patient fibroblasts, RNAi knockdown cells and the Timm8a1 mutant mouse all fail to show the import or respiratory defect that patient lymphoblasts do?
HUMAN MODEL MISMATCH timm8a_tim23_import_in_vivo
Attached to
pathophysiology#Impaired Intermembrane-Space Escort of Hydrophobic Precursors
This is not a clean species gap, and the entry should not be read as one. The disagreement is already present within human patient cells. Patient lymphoblasts carrying DDP1-Q34X showed decreased NADH and defects in mitochondrial protein import (PMID:15254020), while RNAi knockdown and patient fibroblasts showed no effect on respiration or membrane potential and the TIM23 account was framed there as a proposal (PMID:21984432). The mouse then sides with the negative result: Tim23 and Tom40 import and oxidative-phosphorylation biogenesis were assayed in the Timm8a1 mutant and reported unaffected (PMID:32820032), and the same group states in the follow-up that "we and others did not find Tim8a to mediate the biogenesis of Tim23" (PMID:36090790). PMID:40075073 calls the human mechanism controversial outright. So the honest reading is a contested step, not a species artifact, and the contest may be about cell type rather than about the biochemistry: the positive result is in a lymphoid line, the negatives are in fibroblasts, HeLa and whole mouse brain, and none of those is an affected cell type. Two alternative accounts have their own support and do not require TIM23 depletion: neuron-specific complex IV assembly through COX17 (PMID:31682224), and loss of the citrin/aralar1 aspartate-glutamate carriers, whose expression is prominent in large brain neurons (PMID:15254020). The distinction matters practically, because CHCHD2 is currently the only node in this entry with a demonstrated rescue.
Proposed experiments
Assay TIM23 steady-state level and import in patient-derived neurons
tim23_import_in_patient_neurons
Every result on either side of this contradiction comes from a cell type the disease spares: lymphoblasts, fibroblasts, HeLa, and whole mouse brain. The MTS patient iPSC-derived neurons with an isogenic CRISPR control already exist (PMID:40075073), so measuring TIM23 import and steady-state level in them would test the step for the first time in the cell type that actually degenerates, and would discriminate a cell-type explanation of the disagreement from a straightforwardly wrong mechanism.
Readouts
TIM23 steady-state level in patient-derived neurons
pathophysiology#Impaired Intermembrane-Space Escort of Hydrophobic Precursors
Direction: DECREASED
Interpretation: A reduction in the human neuronal context would support the import account; an unchanged level would align the human neuron with the mouse and move the mechanism onto the CHCHD2/complex IV arm.
Would support
pathophysiology#Impaired Intermembrane-Space Escort of Hydrophobic Precursors
Supporting outcome
  • Reduced TIM23 steady-state level and impaired import in patient iPSC-derived neurons relative to the isogenic control.
Refuting outcome
  • TIM23 import and steady-state level indistinguishable from the isogenic control, as in the mutant mouse, despite the complex IV and CHCHD2 phenotype being present.
⚙

Pathophysiology

7
TIMM8A Loss of Function
Hemizygous loss-of-function TIMM8A variants, or contiguous Xq22.1 deletions removing the gene, abolish or destabilize the deafness/dystonia peptide DDP1. The C66W missense change is the best-characterized example: it disrupts Zn2+ coordination by the conserved twin CX3C (Cys4) motif, so the protein is imported and sorted normally but is incorrectly folded.
zinc ion binding by the twin CX3C motif of DDP1 (the missense route to loss of function; frameshift, stop and whole-gene-deletion alleles leave no protein for this state to describe) GO:0008270 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves zinc ion binding by the twin CX3C motif of DDP1 (the missense route to loss of function; frameshift, stop and whole-gene-deletion alleles leave no protein for this state to describe), annotated with zinc ion binding (GO:0008270), qualified as loss of function. GO:0008270 is a molecular function from the Gene Ontology. ⇓ LOSS OF FUNCTION
Downstream
TIM8-TIM13 Chaperone Complex Assembly Failure
Show evidence (2 references)
PMID:8841189 SUPPORT Human Clinical
"We now report small deletions in this candidate gene in the original DFN-1/MTS family, and in a family with deafness, dystonia and mental deficiency but not blindness. This gene, named DDP (deafness/ dystonia peptide), shows high levels of expression in fetal and adult brain."
The positional-cloning report establishing TIMM8A/DDP as the causal gene.
PMID:31903733 SUPPORT In Vitro
"The novel base change in the TIMM8A gene (c.1A>T, p.Met1Leu) results in no detectable protein and a reduction in TIMM8A transcript abundance."
Demonstrates complete loss of the protein for an initiation-codon allele, showing the lesion is loss of function.
TIM8-TIM13 Chaperone Complex Assembly Failure
DDP1 assembles with TIMM13 into a soluble 70 kDa hetero-hexameric chaperone of the mitochondrial intermembrane space. Without functional DDP1 the complex does not form, and the steady-state level of its partner TIMM13 falls with it even though TIMM13 transcript abundance is unchanged.
mitochondrial intermembrane space GO:0005758 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves mitochondrial intermembrane space (GO:0005758). GO:0005758 is a cellular component from the Gene Ontology.
Experimental models
MTS patient dermal fibroblasts PRIMARY CELL CULTURE Directly demonstrates loss of DDP1 and the commensurate fall in its obligate partner in patient-derived cells.
Downstream
Impaired Intermembrane-Space Escort of Hydrophobic Precursors
Show evidence (2 references)
PMID:11875042 SUPPORT In Vitro
"We now show that TIMM8a assembles in a 70 kDa complex in the intermembrane space with TIMM13. DDP1/TIMM8a is not detectable in fibroblasts derived from a patient with a missense mutation in the DDP1/TIMM8a gene"
Establishes the complex and shows the protein is absent in patient fibroblasts.
PMID:31903733 SUPPORT In Vitro
"We observed a commensurate decrease in the steady-state level of the Tim13 protein (the binding partner of Tim8a) but no decrease in TIMM13 transcripts."
Shows the partner protein is destabilized post-transcriptionally when DDP1 is absent, which is what a failed assembly predicts.
Impaired Intermembrane-Space Escort of Hydrophobic Precursors
The DDP1-TIMM13 complex contacts translocation intermediates of human TIM23 directly and is required for its import, so loss of the chaperone impairs delivery of hydrophobic precursors across the aqueous intermembrane space to the inner membrane. The human complex complements the yeast TIM8-TIM13 complex, and the reciprocal yeast mutation destabilizes Tim8p, indicating the step is conserved.
insertion of TIM23 into the mitochondrial inner membrane GO:0045039 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased insertion of TIM23 into the mitochondrial inner membrane, annotated with protein insertion into mitochondrial inner membrane (GO:0045039). GO:0045039 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
Timm8a1 I23fs49X frameshift mouse Mouse fails to recapitulate The mouse does not reproduce the TIM23 import defect that the human and yeast biochemistry places at the centre of the mechanism.
Downstream
Mitochondrial Morphology and Dynamics Disturbance
Neuronal Bioenergetic Failure
Show evidence (7 references)
PMID:11489896 SUPPORT In Vitro
"The DDP1.hTim13 complex is in direct contact with translocation intermediates of human Tim23 in mammalian mitochondria. The human DDP1.hTim13 complex complements the function of the TIM8.13 complex in yeast and facilitates import of yeast and human Tim23."
Direct evidence that the complex acts on TIM23 import, which is the step this node asserts.
PMID:10051608 SUPPORT In Vitro
"The deafness dystonia syndrome thus is a novel type of mitochondrial disease that probably is caused by a defective mitochondrial protein-import system."
The report that reframed the disorder as an import defect rather than a respiratory-subunit defect.
PMID:15254020 SUPPORT In Vitro
"A lymphoblast cell line derived from an MTS patient had decreased NADH levels and defects in mitochondrial protein import."
The human patient-cell result supporting a general import defect. It is one side of a contradiction: see the REFUTE items below and the HUMAN_MODEL_MISMATCH discussion.
+ 4 more references
Mitochondrial Morphology and Dynamics Disturbance
Loss of DDP1 disturbs mitochondrial shape and the fusion-fission balance. The direction of the change is not consistent across systems and this entry does not force it into one: patient fibroblasts and DDP1-knockdown HeLa cells show elongated mitochondrial tubules, patient iPSC-derived neurons show fragmentation, and the mutant mouse hippocampus shows reduced mitochondrial size with upregulated Mtfp1/Mtp18, a positive regulator of fission. Cell type, species and whether the protein is knocked down or absent all differ between these results, so the shared claim is that dynamics are dysregulated, not that mitochondria are uniformly longer or shorter.
mitochondrion organization GO:0007005 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated mitochondrion organization (GO:0007005). GO:0007005 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Animal models
Timm8a1 I23fs49X frameshift mouse Mouse recapitulates Mutant mice show abnormal mitochondrial structure in several brain areas, quantified in hippocampus as reduced mitochondrial size with upregulated Mtfp1/Mtp18, alongside hearing impairment and cognitive deficit.
Downstream
Selective Neurodegeneration of Sensory and Basal Ganglia Neurons
Show evidence (2 references)
PMID:31903733 SUPPORT In Vitro
"Patient fibroblasts exhibited elongation and/or increased fusion of mitochondria, consistent with prior reports."
Documents the altered mitochondrial morphology in patient cells.
PMID:21984432 SUPPORT In Vitro
"Live cell microscopy of primary fibroblasts derived from DDON patients and of DDP1 downregulated HeLa cells displayed alterations of mitochondrial morphology with notable extensions in the length of mitochondrial tubules"
Independent demonstration of the morphology change in both patient cells and an engineered knockdown, and the source of the elongation direction.
Neuronal Bioenergetic Failure
A respiratory deficit that is selective for neurons. hTim8a is required for complex IV assembly in neuronal cells specifically, through a transient interaction with the copper chaperone COX17, and the resulting oxidative stress shifts apoptotic regulators so that cells are primed for death. Patient iPSC-derived neurons show reduced complex IV level and activity, reduced ATP, and increased reactive oxygen species, with CHCHD2 downregulated as a downstream effector. This is the arm of the mechanism that explains why a ubiquitously expressed chaperone produces a disease of neurons, and notably it does not require the contested TIM23 step.
mitochondrial respiratory chain complex IV assembly GO:0033617 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased mitochondrial respiratory chain complex IV assembly (GO:0033617). GO:0033617 is a biological process from the Gene Ontology. ↓ DECREASED
Experimental models
MTS patient iPSC-derived neurons with isogenic CRISPR control IPSC DERIVED MODEL Patient and isogenic-mutant neurons both show reduced complex IV level and activity, reduced ATP, increased reactive oxygen species, and mitochondrial fragmentation, with impaired neuronal differentiation.
Downstream
Selective Neurodegeneration of Sensory and Basal Ganglia Neurons
Show evidence (2 references)
PMID:31682224 SUPPORT In Vitro
"We show that hTim8a is required for the assembly of Complex IV in neurons, which is mediated through a transient interaction with Complex IV assembly factors, in particular the copper chaperone COX17."
Supplies the neuron-selectivity this node asserts: the complex IV requirement is specific to neuronal cells, which is why a ubiquitously expressed chaperone produces a neuronal disease.
PMID:40075073 SUPPORT In Vitro
"Mitochondrial function analysis revealed reduced protein levels and activity of complex IV, diminished ATP synthesis, and increased reactive oxygen species (ROS) generation in MTS- and MUT-neurons."
Establishes the bioenergetic deficit in patient-derived neurons against an isogenic control.
Selective Neurodegeneration of Sensory and Basal Ganglia Neurons
Chronic mitochondrial insufficiency in high-demand post-mitotic neurons produces progressive, spatially selective neuronal loss. Human neuropathology documents loss in the optic nerve, retina, striate cortex, basal ganglia, and dorsal roots of the spinal cord, and near-total loss of cochlear spiral ganglion neurons on temporal-bone study. The temporal separation of the affected populations is what produces the staged clinical course.
cochlear spiral ganglion neuron CL:0011113 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear spiral ganglion neuron, annotated with spiral ganglion neuron (CL:0011113). CL:0011113 is a cell type from the Cell Ontology. retinal ganglion cell CL:0000740 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal ganglion cell (CL:0000740). CL:0000740 is a cell type from the Cell Ontology. striatal neuron (left unbound: the cited neuropathology resolves only to basal ganglia and striatum, and does not identify a neuron subclass) Relation: this pathophysiological event involves this cell type This pathophysiological event involves striatal neuron (left unbound: the cited neuropathology resolves only to basal ganglia and striatum, and does not identify a neuron subclass).
Downstream
Auditory Neuropathy
Dystonia
Ataxia
Optic Atrophy
Dementia
Personality Change
Paranoia
Corticospinal and Bulbar Involvement
Show evidence (2 references)
PMID:11803487 SUPPORT Human Clinical
"The findings included neuronal cell loss in the optic nerve, retina, striate cortex, basal ganglia, and dorsal roots of the spinal cord."
Human neuropathology naming the degenerating populations this node asserts.
PMID:17471106 SUPPORT Human Clinical
"all bones examined showed near-total loss of cochlear neuronal cells and severe loss of vestibular neurons. When compared with age-matched controls, there was 90% to 95% loss of cochlear neurons and 75% to 85% loss of vestibular neurons."
Quantified temporal-bone loss across four affected members of one family, establishing the cochlear ganglion degeneration this node asserts.
Corticospinal and Bulbar Involvement
Degeneration extending to corticospinal and bulbar pathways, producing spasticity and hyperreflexia and, late, the swallowing impairment. Spasticity and dysphagia were part of the original DFN-1 description, and the reported case shows the spastic and bulbar deficits together. This node is what connects dysphagia to the pathograph; the hearing deficit does not cause it.
Downstream
Dysphagia
Show evidence (2 references)
PMID:8841189 SUPPORT Human Clinical
"postlingual progressive sensorineural deafness as the first presenting symptom in early childhood, followed by progressive dystonia, spasticity, dysphagia, mental deterioration, paranoia and cortical blindness"
The original description places spasticity and dysphagia in the syndrome and orders them after the deafness, which is the claim this node makes.
PMID:37325222 SUPPORT Human Clinical
"He did not present any motor deficit but had a generalized increase in muscle tone, especially in the lower limbs, with moderate spasticity and hyperreflexia, with a spastic gait that was impossible without assistance."
Documents the corticospinal signs in the same patient in whom the dysphagia appeared.
✶

Histopathology

2
Cochlear and Vestibular Ganglion Neuronal Loss
Temporal-bone study shows near-complete loss of cochlear ganglion neurons with severe loss of vestibular neurons, while the hair cells of both organs and the geniculate and trigeminal ganglia are preserved — so the degeneration is selective, not a general ganglion-cell loss. The vestibular loss is largely clinically silent.
Show evidence (4 references)
PMID:11449109 SUPPORT Human Clinical
"There was near complete loss of spiral ganglion cells with loss of nearly all peripheral and central processes. Only 1,765 spiral ganglion cells remained (8.5% of mean normal for age). The organ of Corti (including hair cells), stria vascularis, and spiral ligament were preserved."
The decisive observation for this entry: the ganglion is destroyed while the organ of Corti and its hair cells are preserved, which is what makes the lesion retrocochlear rather than cochlear.
PMID:11449109 SUPPORT Human Clinical
"There was also a severe loss of Scarpa's ganglion cells with preservation of vestibular hair cells. The population of geniculate and trigeminal ganglion cells appeared normal."
Documents the vestibular ganglion loss and shows the degeneration is selective rather than a general ganglion-cell loss.
PMID:17471106 SUPPORT Human Clinical
"When compared with age-matched controls, there was 90% to 95% loss of cochlear neurons and 75% to 85% loss of vestibular neurons."
Quantifies the loss across four affected individuals.
+ 1 more reference
Multifocal Central Neuronal Loss
Neuronal loss in the optic nerve, retina, striate cortex, basal ganglia, and dorsal roots of the spinal cord in affected males from two unrelated families carrying different TIMM8A mutations.
Show evidence (1 reference)
PMID:11803487 SUPPORT Human Clinical
"The findings included neuronal cell loss in the optic nerve, retina, striate cortex, basal ganglia, and dorsal roots of the spinal cord."
Direct human neuropathologic description.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Deafness-Dystonia-Optic Neuronopathy Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Digestive 1
Dysphagia HP:0002015 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37325222 SUPPORT Human Clinical
"Severe dysphagia was present during the following weeks after the encephalopathic period, and percutaneous gastrostomy was needed but removed in less than a year."
Documents dysphagia severe enough to require gastrostomy.
Ear 1
Auditory Neuropathy VERY_FREQUENT Sensorineural hearing impairment HP:0000407 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is auditory neuropathy (retrocochlear sensorineural hearing impairment), annotated with Sensorineural hearing impairment (HP:0000407), qualified as course progressive. HP:0000407 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (6 references)
PMID:20301395 SUPPORT Other
"Males with deafness-dystonia-optic neuronopathy (DDON) syndrome have prelingual or postlingual sensorineural hearing impairment in early childhood"
GeneReviews establishes the defining phenotype and its onset.
PMID:30634948 SUPPORT Human Clinical
"Clinically, otological examinations illustrated the typical postsynaptic auditory neuropathy for the proband without the symptoms of dystonia or optic atrophy. MRI demonstrated abnormal small cochlear symmetric nerves"
Documents the auditory-neuropathy pattern and the small cochlear nerves that go with a neural lesion.
PMID:20301395 SUPPORT Other
"The hearing impairment appears to be consistent in age of onset and progression, whereas the neurologic, visual, and neuropsychiatric signs vary in degree of severity and rate of progression."
Supports treating hearing loss as the consistent anchor of the phenotype while the later features vary.
+ 3 more references
Eye 1
Optic Atrophy FREQUENT HP:0000648 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Optic atrophy (HP:0000648), qualified as course progressive. HP:0000648 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"slowly progressive decreased visual acuity from optic atrophy beginning at approximately age 20 years"
GeneReviews gives the phenotype and its onset age.
Nervous System 6
Dystonia FREQUENT HP:0001332 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dystonia (HP:0001332), qualified as course progressive. HP:0001332 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"slowly progressive dystonia or ataxia in the teens"
GeneReviews gives the phenotype, its course, and its onset decade.
Ataxia HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251), qualified as course progressive. HP:0001251 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"slowly progressive dystonia or ataxia in the teens"
GeneReviews names ataxia as an alternative to dystonia in the same phase, and gives its onset decade.
Dementia HP:0000726 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dementia (HP:0000726), qualified as course progressive. HP:0000726 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"dementia beginning at approximately age 40 years"
GeneReviews gives the phenotype and its onset age.
Personality Change FREQUENT Personality changes HP:0000751 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Personality changes (HP:0000751), qualified as course progressive; childhood onset. HP:0000751 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE Onset: CHILDHOOD
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"Psychiatric symptoms such as personality change and paranoia may appear in childhood and progress."
GeneReviews establishes personality change, its childhood onset, and its progressive course.
Paranoia HP:0011999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Paranoia (HP:0011999), qualified as course progressive; childhood onset. HP:0011999 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE Onset: CHILDHOOD
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"Psychiatric symptoms such as personality change and paranoia may appear in childhood and progress."
The same GeneReviews sentence names paranoia as a distinct symptom, so it is curated separately rather than folded into a generic behavioural term.
Basal Ganglia Iron Accumulation Iron accumulation in brain HP:0012675 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Iron accumulation in brain (HP:0012675). HP:0012675 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40597358 SUPPORT Human Clinical
"A 16-year-old male was referred for genetic evaluation due to a 6-year history of progressive dystonia, motor coordination difficulties, and iron deposits in the basal ganglia detected by brain MRI."
Reports the imaging finding this phenotype records.
🧬

Genetic Associations

1
TIMM8A
Gene: TIMM8A hgnc:11817 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TIMM8A (hgnc:11817). hgnc:11817 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
X-linked recessive
Show evidence (2 references)
PMID:31903733 SUPPORT Human Clinical
"The TIMM8A gene product localizes to the intermembrane space in mitochondria where it functions in the import of nuclear-encoded proteins into the mitochondrial inner membrane. Frameshifts or premature stops represent the majority of mutations in TIMM8A that cause DDON syndrome."
Establishes the gene product's localization, function, and variant spectrum.
PMID:40075073 SUPPORT Human Clinical
"The human TIMM8A gene consists of one intron and two exons, encoding a 97-amino acid protein, TIMM8a/DDP1, which is located in the intermembrane space (IMS) of mitochondria"
Gives the gene structure and protein size stated in this entry.
💊

Medical Actions

5
Cochlear Device Implantation
Action: cochlear device implantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cochlear device implantation, annotated with Surgical Procedure (NCIT:C15329), qualified as medical device cochlear implant. NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Platform: Device
Cochlear implantation is attempted and has been performed in DDON, but benefit is variable and generally less than in hair-cell sensorineural deafness. The reason is specific and follows from the pathograph: an implant works by bypassing the hair cells and electrically stimulating the spiral ganglion neurons directly, and in this disease those neurons are the population that has degenerated - 8.5% of the age-normal count remained in the case with a cytocochleogram, in an ear whose organ of Corti and hair cells were preserved. The device's target is what the disease destroys, which is the opposite of the usual indication.
Mechanism Target:
Auditory Neuropathy — Addresses the hearing phenotype symptomatically. It cannot restore the spiral ganglion neurons it depends on for stimulation, which is why benefit is limited and variable.
Show evidence (3 references)
PMID:20301395 SUPPORT INDIRECT Other
"Because auditory neuronopathy is the cause of the hearing loss, hearing aids have only variable success."
GeneReviews states the mechanistic principle - the neural basis of the loss limits what a peripheral device achieves. Graded INDIRECT because it is stated of hearing aids, and this entry applies it to implantation.
PMID:31903733 SUPPORT Human Clinical
"at age 6 years received cochlear implants"
Establishes that implantation is actually performed in this disease, which the GeneReviews hearing-aid statement does not.
PMID:11449109 SUPPORT Human Clinical
"Only 1,765 spiral ganglion cells remained (8.5% of mean normal for age). The organ of Corti (including hair cells), stria vascularis, and spiral ligament were preserved."
Quantifies the depletion of the exact neuronal population a cochlear implant stimulates, which is the mechanistic basis for the limited benefit this entry describes.
Physical and Occupational Therapy
Action: physical therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is physical therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
Platform: Behavioral / lifestyle
Physical medicine and rehabilitation to improve fine and gross motor skills and mobility, prevent contractures, and provide adaptive devices for activities of daily living.
Mechanism Target:
Dystonia — Symptomatic management of the movement disorder and its complications.
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"Physical medicine and rehabilitation, physical and occupational therapy to improve fine and gross motor skills and mobility, to prevent contractures, and to provide adaptive devices to improve activities of daily living."
GeneReviews management recommendation for the motor phenotype.
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Counseling for carrier females. The chance of transmitting the variant is 50% per pregnancy, which is not the same as a 50% chance of an affected child: sons who inherit it are affected, while daughters who inherit it are heterozygotes who may have only mild hearing impairment and focal dystonia. Prenatal and preimplantation testing are available once the familial variant is known. The 2023 four-affected-male family report makes the case that timely etiologic investigation of childhood hearing loss is what brings this within reach.
Show evidence (3 references)
PMID:37325222 SUPPORT Human Clinical
"Recurrence risk is high for female carriers, and reproductive options should be offered."
Directly supports counseling as a management component.
PMID:20301395 SUPPORT Other
"the chance of transmitting the genetic alteration in each pregnancy is 50%"
The source of the quantitative recurrence risk this treatment states. The case report cited above says only that the risk is high.
PMID:20301395 SUPPORT Other
"Prenatal diagnosis for a pregnancy at increased risk and preimplantation genetic testing are possible if the DDON-causing genetic alteration in the family is known."
Supports the reproductive-testing options named here, including the condition that the familial variant must already be identified.
Antioxidant Rescue (preclinical only)
Action: antioxidant supplementation (investigational, cell models only)NCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antioxidant supplementation (investigational, cell models only), annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Agent: vitamin E CHEBI:33234 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses vitamin E (CHEBI:33234). CHEBI:33234 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Not a clinical treatment, and recorded here as the only pharmacological lead in the cited literature. In neuronal cells lacking hTim8a the complex IV assembly defect produces oxidative stress that primes the cells for apoptosis, and relieving that stress with vitamin E rescues them. This is a cell-culture result with no human evidence in DDON; it is curated so the lead is findable, not to imply a therapy.
Mechanism Target:
Neuronal Bioenergetic Failure — Acts on the oxidative-stress consequence of the complex IV assembly defect, not on the assembly defect itself.
Show evidence (1 reference)
PMID:31682224 SUPPORT In Vitro
"Alleviation of oxidative stress with Vitamin E treatment rescues cells from apoptotic vulnerability."
The rescue result this entry records. In vitro only, which is why the treatment is labelled preclinical.
Supportive and Multidisciplinary Care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
There is no disease-modifying therapy. Management is supportive: standard treatment of psychiatric issues, deaf-blind service referral and tactile sign language as vision loss compounds the deafness, feeding support for dysphagia, and surveillance. The surveillance quoted below is neurologic, developmental, speech-language and vision assessment plus physical and occupational therapy review; audiologic follow-up is standard practice in a disease whose presenting feature is hearing loss, but it is not part of the GeneReviews surveillance recommendation and is not claimed as one here.
Show evidence (2 references)
PMID:20301395 SUPPORT Other
"Educational programs for developmental and sensory deficits, including training in tactile sign language."
GeneReviews management recommendation for combined sensory loss.
PMID:20301395 SUPPORT Other
"Regular neurologic evaluation and assessment for dementia and/or psychiatric manifestations; annual developmental, speech-language, and vision assessments in childhood"
Supports the surveillance this treatment describes, which was previously asserted without a quoted source.
🔬

Diagnosis

2
Auditory Neuropathy Electrophysiologic Signature
Preserved otoacoustic emissions with absent or abnormal auditory brainstem response and absent stapedial reflex, in a structurally normal inner ear, in a male with early-onset hearing loss. Because this pattern separates a neural from a hair-cell lesion, it is the practical entry point to the diagnosis and the reason TIMM8A belongs on auditory-neuropathy sequencing panels.
Show evidence (3 references)
PMID:30634948 SUPPORT Human Clinical
"Furthermore, we found another two TIMM8A variations, the deletion c.133_135delGAG and a copy number variation (CNV) including the TIMM8A gene, in two independent case, when we performed NGS on an auditory neuropathy population."
Shows TIMM8A variants being recovered by sequencing an auditory-neuropathy cohort, which is what makes this signature diagnostically useful.
PMID:11449109 SUPPORT Human Clinical
"Sensorineural hearing loss in Mohr-Tranebjaerg syndrome is the result of a postnatal, progressive, severe auditory neuropathy."
Establishes the auditory-neuropathy character of the deficit that the electrophysiologic signature in this node detects.
PMID:30634948 SUPPORT Human Clinical
"MRI demonstrated abnormal small cochlear symmetric nerves"
Qualifies this node's "structurally normal inner ear" framing: the labyrinth is normal, but the cochlear nerves themselves may be visibly small, which is itself consistent with a neural rather than cochlear lesion.
Molecular Testing Including Deletion Analysis
Sequence analysis of TIMM8A detects roughly half of cases; the remainder are contiguous Xq22.1 deletions that require deletion/duplication analysis or chromosomal microarray. Sequence-only testing therefore misses about half of affected individuals, and microarray is specifically indicated where co-occurring agammaglobulinemia suggests a BTK-spanning deletion.
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"The diagnosis of DDON syndrome is established in either a male proband who has a hemizygous TIMM8A pathogenic variant (~50% of affected males) or a female proband who has a heterozygous TIMM8A pathogenic variant (~50% of affected females) or a contiguous gene deletion of Xq22.1 involving TIMM8A..."
GeneReviews gives the split between sequence-detectable and deletion-detectable cases.
📈

Progression

4
Stage 1 - isolated auditory neuropathy
Age: early childhood
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"prelingual or postlingual sensorineural hearing impairment in early childhood"
GeneReviews places the hearing loss first and in early childhood.
Stage 2 - dystonia or ataxia added
Age: teens
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"slowly progressive dystonia or ataxia in the teens"
GeneReviews places the movement disorder in the second decade.
Stage 3 - optic atrophy added
Age: from approximately age 20 years
Show evidence (1 reference)
PMID:20301395 SUPPORT Other
"slowly progressive decreased visual acuity from optic atrophy beginning at approximately age 20 years"
GeneReviews places the visual decline in the third decade.
Stage 4 - dementia added
Age: from approximately age 40 years
The staging is by system involvement, not a formal numeric staging system. Only the hearing loss is consistent in onset and rate; the later phases vary widely in severity and speed, and lifespan varies within a single family.
Show evidence (2 references)
PMID:20301395 SUPPORT Other
"dementia beginning at approximately age 40 years"
GeneReviews places cognitive decline in the fifth decade.
PMID:20301395 SUPPORT Other
"The hearing impairment appears to be consistent in age of onset and progression, whereas the neurologic, visual, and neuropsychiatric signs vary in degree of severity and rate of progression."
Supports the caveat in this phase's notes that only the first stage is predictable.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
No population-based prevalence or incidence estimate exists. The literature is a case-series aggregate: the deep-research report records 91 affected individuals in 37 families from GeneReviews and 69 cases reported worldwide since 1960 from a 2019 cohort paper, but neither figure appears in a cached abstract, so no numeric rate is asserted here. The deep-research report also carries a diagnostic-yield figure of 3/168 from a targeted auditory-neuropathy sequencing cohort; that figure is likewise absent from the cached abstract, so it is not curated anywhere in this entry, and the diagnosis section quotes the cohort finding qualitatively instead.
🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Deafness-Dystonia-Optic Neuronopathy Syndrome:

Usher syndrome
Overlapping Features Also combines deafness with progressive visual loss, but the visual lesion is a retinal dystrophy with an abnormal electroretinogram, whereas DDON has optic atrophy with a typically normal electroretinogram.
Wolfram syndrome
Overlapping Features Also combines hearing loss with optic atrophy, but is distinguished by juvenile-onset diabetes mellitus and the absence of dystonia.
MEGDEL syndrome
Overlapping Features SERAC1-related deafness-dystonia, distinguished by Leigh-like MRI features and 3-methylglutaconic aciduria.
Arts syndrome
Overlapping Features PRPS1-related X-linked disorder in which hearing loss predominates without the dystonia of DDON.
🧫

Experimental Models

2
MTS patient iPSC-derived neurons with isogenic CRISPR control IPSC_DERIVED_MODEL
iPSCs from a male MTS patient carrying TIMM8A c.225-229del (p.Q75fs95*), differentiated into neurons and compared against both a healthy control line and an isogenic control into which the same mutation was introduced by CRISPR/Cas9. The isogenic arm is what lets the neuronal phenotype be attributed to the variant rather than to line background.
Publication
PMID:40075073
Pathograph links
Neuronal Bioenergetic Failure recapitulates fidelity: high observes: cellular Patient and isogenic-mutant neurons both show reduced complex IV level and activity, reduced ATP, increased reactive oxygen species, and mitochondrial fragmentation, with impaired neuronal differentiation.
Limitations: A cell model cannot report the staged, decades-long selectivity of the human disease across auditory, basal ganglia, and visual populations.
Readouts
Complex IV protein level and activity
Direction: DECREASED
Interpretation: Bioenergetic correlate of the neuronal mitochondrial deficit.
Show evidence (1 reference)
PMID:40075073 SUPPORT In Vitro
"Mitochondrial function analysis revealed reduced protein levels and activity of complex IV, diminished ATP synthesis, and increased reactive oxygen species (ROS) generation in MTS- and MUT-neurons."
Reports the complex IV measurement behind this readout.
CHCHD2 rescue of neurite outgrowth
Direction: RESTORED
Interpretation: Overexpressing CHCHD2 reverses the mitochondrial and neurite phenotype, placing CHCHD2 downstream of TIMM8a loss.
Show evidence (1 reference)
PMID:40075073 SUPPORT In Vitro
"Overexpression of CHCHD2 rescued mitochondrial dysfunction and promoted neurite elongation in MTS-neurons, suggesting that CHCHD2 acts as a downstream effector of TIMM8a in the pathogenesis of MTS."
Reports the rescue measurement behind this readout.
Show evidence (1 reference)
PMID:40075073 SUPPORT In Vitro
"Mitochondrial function analysis revealed reduced protein levels and activity of complex IV, diminished ATP synthesis, and increased reactive oxygen species (ROS) generation in MTS- and MUT-neurons."
Supports this human cell model as informative for the node.
MTS patient dermal fibroblasts PRIMARY_CELL_CULTURE
Patient fibroblasts carrying C66W or p.Met1Leu, used to show absence of TIMM8a protein, reduced steady-state TIMM13, and altered mitochondrial morphology.
Publication
PMID:31903733
Pathograph links
TIM8-TIM13 Chaperone Complex Assembly Failure recapitulates fidelity: high observes: molecular Directly demonstrates loss of DDP1 and the commensurate fall in its obligate partner in patient-derived cells.
Limitations: Fibroblasts are not an affected cell type in this disease, so they report the molecular lesion but not the neuron-selective consequence.
Show evidence (1 reference)
PMID:31903733 SUPPORT In Vitro
"We observed a commensurate decrease in the steady-state level of the Tim13 protein (the binding partner of Tim8a) but no decrease in TIMM13 transcripts."
Supports the fibroblast model as informative for complex assembly.
🐁

Animal Models

1
Timm8a1 I23fs49X frameshift mouse
A CRISPR/Cas9 knock-in mouse carrying a frameshift in the murine ortholog, generated alongside the characterization of a family carrying a novel hemizygous DDP1 variant.
Species
Mouse
Genotype
Timm8a1 p.I23fs49X hemizygous (CRISPR/Cas9)
Publication
PMID:32820032
Pathograph links
Mitochondrial Morphology and Dynamics Disturbance recapitulates fidelity: moderate observes: cellular Mutant mice show abnormal mitochondrial structure in several brain areas, quantified in hippocampus as reduced mitochondrial size with upregulated Mtfp1/Mtp18, alongside hearing impairment and cognitive deficit.
Limitations: The direction differs from the human cell result: mouse hippocampal mitochondria are smaller, whereas patient fibroblasts and knockdown HeLa cells show elongation. The node is scoped to dysregulated dynamics rather than a direction for this reason, but a reader should not take the mouse as evidence for the human direction. The mouse also shows the organelle change without frank hippocampal neuronal loss, so it models this node and not the degeneration downstream of it.
Readouts
Mitochondrial ultrastructure in brain
Direction: ALTERED
Interpretation: Electron-microscopic correlate of the mitochondrial arm of this node in the mouse.
Show evidence (1 reference)
PMID:32820032 SUPPORT Model Organism
"Electron microscopic analysis of brain samples from the mutant mice indicated abnormal mitochondrial structure in several brain areas."
Reports the ultrastructural measurement behind this readout.
Hippocampal mitochondrial size and Mtfp1/Mtp18 level
Direction: DECREASED
Interpretation: Mitochondrial size falls without frank neuronal loss, and the reduction tracks upregulation of the fission factor Mtfp1/Mtp18. In this model the organelle phenotype therefore precedes, rather than follows, neuronal death.
Show evidence (2 references)
PMID:36090790 SUPPORT Model Organism
"Although the general neuronal loss was not found in the hippocampus of the MUT genotype, EM assessment indicated that the mitochondrial size showing as aspect ratio and form factor in the hippocampus of the MUT strain was significantly reduced compared to that in the WT genotype."
Reports the quantitative measurement behind this readout, and is the primary source for the mitochondrial-size finding.
+ 1 more reference
Show evidence (1 reference)
PMID:32820032 SUPPORT Model Organism
"Electron microscopic analysis of brain samples from the mutant mice indicated abnormal mitochondrial structure in several brain areas."
Supports the model as informative for the mitochondrial phenotype.
Impaired Intermembrane-Space Escort of Hydrophobic Precursors fails to recapitulate fidelity: low observes: molecular The mouse does not reproduce the TIM23 import defect that the human and yeast biochemistry places at the centre of the mechanism.
Limitations: Tim23 and Tom40 import and oxidative-phosphorylation biogenesis were all unaffected in the mutant mouse. This is the substantive negative result of the model: the animal has the disease-relevant hearing and cognitive phenotypes without the import lesion, so either the murine ortholog is functionally redundant for this step or the import defect is not the whole mechanism in vivo.
Show evidence (1 reference)
PMID:32820032 SUPPORT Model Organism
"However, Timm8a1I23fs49X/y mutation did not affect the import of mitochondria inner member protein Tim23 and outer member protein Tom40 as well as the biogenesis of the proteins in the mitochondrial oxidative phosphorylation system and the manganese superoxide dismutase (MnSOD / SOD-2)."
Supports this FAILS_TO_RECAPITULATE link: the assay was done and reported negative, so the quote establishes the failure the link asserts. It contradicts the import account, not the link.
Show evidence (1 reference)
PMID:32820032 SUPPORT Model Organism
"The male mice with Timm8a1I23fs49X/y mutant exhibited less weight gain, hearing impairment and cognitive deficit."
Establishes that the model reproduces the cardinal auditory and cognitive phenotypes, which is what makes it informative despite the import result.
{ }

Source YAML

click to show 
name: Deafness-Dystonia-Optic Neuronopathy Syndrome
creation_date: "2026-09-04T00:00:00Z"
category: Genetic
parents:
- Mitochondrial Disease
- Inherited Neurodegenerative Disorder
- X-Linked Disorder
synonyms:
- Mohr-Tranebjaerg syndrome
- MTS
- DDON syndrome
- deafness dystonia syndrome
- deafness-dystonia-optic neuronopathy syndrome
- DFN-1
- Jensen syndrome
- DDP
disease_term:
  preferred_term: deafness dystonia syndrome
  term:
    id: MONDO:0010578
    label: deafness dystonia syndrome
description: >-
  Deafness-dystonia-optic neuronopathy (DDON) syndrome, universally known in the
  clinical literature as Mohr-Tranebjaerg syndrome, is an X-linked recessive
  neurodegenerative disorder caused by loss of function of TIMM8A, which encodes
  the 97-amino-acid deafness/dystonia peptide DDP1 of the mitochondrial
  intermembrane space. Affected males follow a stereotyped four-stage sequence:
  prelingual or postlingual sensorineural hearing impairment in early childhood,
  slowly progressive dystonia or ataxia in the teens, decreased visual acuity
  from optic atrophy from about age 20, and dementia from about age 40.
  Psychiatric features do not belong to that last stage — personality change and
  paranoia may appear in childhood and progress alongside everything else.

  Two features distinguish this entry from a generic syndromic hearing-loss
  entry. First, the deafness is an auditory neuropathy: the lesion is
  retrocochlear, with near-total loss of cochlear spiral ganglion neurons on
  temporal-bone histopathology while the cochlear hair cells are comparatively
  spared. That is not a descriptive detail — it is why hearing aids and cochlear
  implantation have only variable success, and it makes the treatment section a
  consequence of the pathograph rather than a separate list. Second, the disorder
  was among the first framed as a mitochondrial disease of the protein-import
  machinery rather than of an oxidative-phosphorylation subunit: DDP1 partners
  with TIMM13 as a hexameric intermembrane-space chaperone that escorts
  hydrophobic precursors, notably TIM23, to the inner membrane.

  How that molecular lesion becomes a neuron-selective disease is not settled.
  The TIM23-import account rests on human and yeast in-vitro and in-organello
  work, but the Timm8a1 mutant mouse shows hearing and cognitive impairment with
  abnormal mitochondrial structure and yet no detectable defect in Tim23 import
  or in oxidative-phosphorylation biogenesis, and a 2025 patient-iPSC study calls
  the cross-membrane transport mechanism in humans controversial while locating
  the neuronal defect in complex IV assembly and a downstream fall in CHCHD2.
  This entry curates both readings and records the mismatch rather than
  harmonizing them.
references:
- reference: PMID:20301395
  title: Deafness-Dystonia-Optic Neuronopathy Syndrome.
  tags:
  - GeneReviews
mappings:
  mondo_mappings:
  - mapping_predicate: skos:exactMatch
    term:
      id: MONDO:0010578
      label: deafness dystonia syndrome
inheritance:
- name: X-linked recessive
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  description: >-
    Hemizygous males are essentially fully penetrant for the classic phenotype.
    Heterozygous females may have mild hearing impairment and focal dystonia;
    this is attributed to skewed X-chromosome inactivation rather than to a
    discrete modifier locus.
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      DDON syndrome is inherited in an X-linked manner.
    explanation: GeneReviews states the mode of inheritance.
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      females who inherit the genetic alteration will be heterozygotes and may
      have mild hearing impairment and focal dystonia
    explanation: Establishes the carrier-female phenotype.
has_subtypes:
- name: Intragenic TIMM8A
  display_name: Intragenic TIMM8A variant (isolated DDON syndrome)
  classification: molecular
  description: >-
    Point mutations, frameshifts, and small indels confined to TIMM8A, producing
    DDON syndrome without immunodeficiency. Reported alleles include the
    structurally characterized C66W missense change, the initiation-codon variant
    p.Met1Leu, and frameshifts such as p.His21Argfs*11 and p.Gln75fs95*.
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      a male proband who has a hemizygous TIMM8A pathogenic variant (~50% of
      affected males)
    explanation: GeneReviews gives the share of cases due to intragenic variants.
- name: Contiguous Xq22.1 deletion
  display_name: Contiguous Xq22.1 deletion (with X-linked agammaglobulinemia when BTK is included)
  classification: molecular
  description: >-
    Deletions at Xq22.1 removing TIMM8A together with neighbouring genes. Where
    the deletion extends into BTK, which lies telomeric to TIMM8A, the patient
    additionally has X-linked agammaglobulinemia and needs immunoglobulin
    replacement. The immunodeficiency is a consequence of the deletion size, not
    of TIMM8A loss, so it is curated here and not as a pathophysiology node.
  evidence:
  - reference: PMID:37325222
    reference_title: "Case report: Mohr-Tranebjaerg syndrome: hearing impairment as the onset of an insidious disorder with high recurrence risk."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      When the contiguous gene deletion includes BTK, located telomeric to
      TIMM8A, it additionally results in X-linked agammaglobulinemia
    explanation: >-
      States that the immunodeficiency arises from co-deletion of BTK rather than
      from TIMM8A loss.
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      a contiguous gene deletion of Xq22.1 involving TIMM8A (~50% of affected
      males and females)
    explanation: GeneReviews gives the share of cases due to contiguous deletion.
  - reference: PMID:36056138
    reference_title: "Identification and analysis of deletion breakpoints in four Mohr-Tranebjærg syndrome (MTS) patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The contiguous gene deletions most commonly include the BTK gene (MIM:
      #300,300), which is located less than one kb downstream of TIMM8A, but
      larger deletions involving additional genes in the region have also been
      described
    explanation: >-
      Primary deletion-architecture source. The sub-kilobase distance between
      TIMM8A and BTK is why this subtype exists at all: the two genes are close
      enough that a deletion large enough to remove one usually removes the
      other.
  - reference: PMID:36056138
    reference_title: "Identification and analysis of deletion breakpoints in four Mohr-Tranebjærg syndrome (MTS) patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two of the XLA-MTS cases presented with large deletions (63.5 and 27.2
      kb), and the junctional regions were characterized by long stretches of
      microhomology, indicating that the events have emerged through homologous
      recombination.
    explanation: >-
      Gives the deletion sizes and the recombination mechanism generating them,
      which is the molecular basis of this subtype rather than of TIMM8A loss.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    No population-based prevalence or incidence estimate exists. The literature
    is a case-series aggregate: the deep-research report records 91 affected
    individuals in 37 families from GeneReviews and 69 cases reported worldwide
    since 1960 from a 2019 cohort paper, but neither figure appears in a cached
    abstract, so no numeric rate is asserted here. The deep-research report also
    carries a diagnostic-yield figure of 3/168 from a targeted
    auditory-neuropathy sequencing cohort; that figure is likewise absent from
    the cached abstract, so it is not curated anywhere in this entry, and the
    diagnosis section quotes the cohort finding qualitatively instead.
progression:
- phase: Stage 1 - isolated auditory neuropathy
  age_range: early childhood
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      prelingual or postlingual sensorineural hearing impairment in early
      childhood
    explanation: GeneReviews places the hearing loss first and in early childhood.
- phase: Stage 2 - dystonia or ataxia added
  age_range: teens
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      slowly progressive dystonia or ataxia in the teens
    explanation: GeneReviews places the movement disorder in the second decade.
- phase: Stage 3 - optic atrophy added
  age_range: from approximately age 20 years
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      slowly progressive decreased visual acuity from optic atrophy beginning at
      approximately age 20 years
    explanation: GeneReviews places the visual decline in the third decade.
- phase: Stage 4 - dementia added
  age_range: from approximately age 40 years
  notes: >-
    The staging is by system involvement, not a formal numeric staging system.
    Only the hearing loss is consistent in onset and rate; the later phases vary
    widely in severity and speed, and lifespan varies within a single family.
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      dementia beginning at approximately age 40 years
    explanation: GeneReviews places cognitive decline in the fifth decade.
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The hearing impairment appears to be consistent in age of onset and
      progression, whereas the neurologic, visual, and neuropsychiatric signs
      vary in degree of severity and rate of progression.
    explanation: >-
      Supports the caveat in this phase's notes that only the first stage is
      predictable.
pathophysiology:
- name: TIMM8A Loss of Function
  biological_scale: MOLECULAR
  description: >-
    Hemizygous loss-of-function TIMM8A variants, or contiguous Xq22.1 deletions
    removing the gene, abolish or destabilize the deafness/dystonia peptide DDP1.
    The C66W missense change is the best-characterized example: it disrupts Zn2+
    coordination by the conserved twin CX3C (Cys4) motif, so the protein is
    imported and sorted normally but is incorrectly folded.
  molecular_functions:
  - preferred_term: >-
      zinc ion binding by the twin CX3C motif of DDP1 (the missense route to
      loss of function; frameshift, stop and whole-gene-deletion alleles leave
      no protein for this state to describe)
    modifier: LOSS_OF_FUNCTION
    term:
      id: GO:0008270
      label: zinc ion binding
  downstream:
  - target: TIM8-TIM13 Chaperone Complex Assembly Failure
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:11956200
      reference_title: "The C66W mutation in the deafness dystonia peptide 1 (DDP1) affects the formation of functional DDP1.TIM13 complexes in the mitochondrial intermembrane space."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        The C66W mutation impairs binding of Zn(2+) ions via the Cys(4) motif. As
        a consequence, the mutated DDP1 is incorrectly folded and loses its
        ability to assemble into a hetero-hexameric 70-kDa complex with its
        cognate partner protein human Tim13.
      explanation: >-
        Traces the causal step from the variant to failed complex assembly in the
        same experiment.
  evidence:
  - reference: PMID:8841189
    reference_title: "A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We now report small deletions in this candidate gene in the original
      DFN-1/MTS family, and in a family with deafness, dystonia and mental
      deficiency but not blindness. This gene, named DDP (deafness/ dystonia
      peptide), shows high levels of expression in fetal and adult brain.
    explanation: The positional-cloning report establishing TIMM8A/DDP as the causal gene.
  - reference: PMID:31903733
    reference_title: "Functional analysis of a novel mutation in the TIMM8A gene that causes deafness-dystonia-optic neuronopathy syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The novel base change in the TIMM8A gene (c.1A>T, p.Met1Leu) results in no
      detectable protein and a reduction in TIMM8A transcript abundance.
    explanation: >-
      Demonstrates complete loss of the protein for an initiation-codon allele,
      showing the lesion is loss of function.
- name: TIM8-TIM13 Chaperone Complex Assembly Failure
  biological_scale: MOLECULAR
  description: >-
    DDP1 assembles with TIMM13 into a soluble 70 kDa hetero-hexameric chaperone
    of the mitochondrial intermembrane space. Without functional DDP1 the complex
    does not form, and the steady-state level of its partner TIMM13 falls with it
    even though TIMM13 transcript abundance is unchanged.
  cellular_components:
  - preferred_term: mitochondrial intermembrane space
    term:
      id: GO:0005758
      label: mitochondrial intermembrane space
  downstream:
  - target: Impaired Intermembrane-Space Escort of Hydrophobic Precursors
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:11875042
    reference_title: "Human deafness dystonia syndrome is caused by a defect in assembly of the DDP1/TIMM8a-TIMM13 complex."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We now show that TIMM8a assembles in a 70 kDa complex in the intermembrane
      space with TIMM13. DDP1/TIMM8a is not detectable in fibroblasts derived
      from a patient with a missense mutation in the DDP1/TIMM8a gene
    explanation: >-
      Establishes the complex and shows the protein is absent in patient
      fibroblasts.
  - reference: PMID:31903733
    reference_title: "Functional analysis of a novel mutation in the TIMM8A gene that causes deafness-dystonia-optic neuronopathy syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We observed a commensurate decrease in the steady-state level of the Tim13
      protein (the binding partner of Tim8a) but no decrease in TIMM13
      transcripts.
    explanation: >-
      Shows the partner protein is destabilized post-transcriptionally when DDP1
      is absent, which is what a failed assembly predicts.
- name: Impaired Intermembrane-Space Escort of Hydrophobic Precursors
  biological_scale: MOLECULAR
  description: >-
    The DDP1-TIMM13 complex contacts translocation intermediates of human TIM23
    directly and is required for its import, so loss of the chaperone impairs
    delivery of hydrophobic precursors across the aqueous intermembrane space to
    the inner membrane. The human complex complements the yeast TIM8-TIM13
    complex, and the reciprocal yeast mutation destabilizes Tim8p, indicating the
    step is conserved.
  biological_processes:
  - preferred_term: insertion of TIM23 into the mitochondrial inner membrane
    modifier: DECREASED
    term:
      id: GO:0045039
      label: protein insertion into mitochondrial inner membrane
  downstream:
  - target: Mitochondrial Morphology and Dynamics Disturbance
    causal_link_type: DIRECT
  - target: Neuronal Bioenergetic Failure
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:11489896
    reference_title: "Role of the deafness dystonia peptide 1 (DDP1) in import of human Tim23 into the inner membrane of mitochondria."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The DDP1.hTim13 complex is in direct contact with translocation
      intermediates of human Tim23 in mammalian mitochondria. The human
      DDP1.hTim13 complex complements the function of the TIM8.13 complex in
      yeast and facilitates import of yeast and human Tim23.
    explanation: >-
      Direct evidence that the complex acts on TIM23 import, which is the step
      this node asserts.
  - reference: PMID:10051608
    reference_title: "Human deafness dystonia syndrome is a mitochondrial disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The deafness dystonia syndrome thus is a novel type of mitochondrial
      disease that probably is caused by a defective mitochondrial protein-import
      system.
    explanation: >-
      The report that reframed the disorder as an import defect rather than a
      respiratory-subunit defect.
  - reference: PMID:15254020
    reference_title: "The calcium-binding aspartate/glutamate carriers, citrin and aralar1, are new substrates for the DDP1/TIMM8a-TIMM13 complex."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      A lymphoblast cell line derived from an MTS patient had decreased NADH
      levels and defects in mitochondrial protein import.
    explanation: >-
      The human patient-cell result supporting a general import defect. It is
      one side of a contradiction: see the REFUTE items below and the
      HUMAN_MODEL_MISMATCH discussion.
  - reference: PMID:21984432
    reference_title: "Alterations in expression levels of deafness dystonia protein 1 affect mitochondrial morphology."
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: >-
      Of note, knockdown of the TIMM8A gene by RNA interference did not show an
      influence on the oxygen respiration rate and the mitochondrial membrane
      potential.
    explanation: >-
      A human-cell negative. If loss of the chaperone broadly disabled inner
      membrane import, respiration and membrane potential would be expected to
      suffer; they did not.
  - reference: PMID:21984432
    reference_title: "Alterations in expression levels of deafness dystonia protein 1 affect mitochondrial morphology."
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: >-
      Deficiencies in the biogenesis of hTim23 and consecutive alterations in
      biogenesis of inner membrane and matrix proteins have been proposed to
      serve as one possible mechanistic explanation.
    explanation: >-
      The authors frame the TIM23 account as one proposal among possible
      explanations rather than an established mechanism, which is the epistemic
      status this node records.
  - reference: PMID:36090790
    reference_title: "Reduced mitochondrial size in hippocampus and psychiatric behavioral changes in the mutant mice with homologous mutation of Timm8a1-I23fs49X."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: >-
      However, we and others did not find Tim8a to mediate the biogenesis of
      Tim23, nor Tom proteins.
    explanation: >-
      A first-person negative from a group that assayed it directly, aligning
      the mouse result with the human fibroblast result against the TIM23
      account.
  - reference: PMID:40075073
    reference_title: "CHCHD2 rescues the mitochondrial dysfunction in iPSC-derived neurons from patient with Mohr-Tranebjaerg syndrome."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: >-
      However, it remains controversial whether the same mechanism exists in
      humans
    explanation: >-
      Records that the field itself treats the human cross-membrane transport
      mechanism as unsettled. Graded INDIRECT because it characterizes the
      state of the evidence rather than testing the step.
- name: Mitochondrial Morphology and Dynamics Disturbance
  biological_scale: CELLULAR
  description: >-
    Loss of DDP1 disturbs mitochondrial shape and the fusion-fission balance.
    The direction of the change is not consistent across systems and this entry
    does not force it into one: patient fibroblasts and DDP1-knockdown HeLa
    cells show elongated mitochondrial tubules, patient iPSC-derived neurons
    show fragmentation, and the mutant mouse hippocampus shows reduced
    mitochondrial size with upregulated Mtfp1/Mtp18, a positive regulator of
    fission. Cell type, species and whether the protein is knocked down or
    absent all differ between these results, so the shared claim is that
    dynamics are dysregulated, not that mitochondria are uniformly longer or
    shorter.
  biological_processes:
  - preferred_term: mitochondrion organization
    modifier: DYSREGULATED
    term:
      id: GO:0007005
      label: mitochondrion organization
  downstream:
  - target: Selective Neurodegeneration of Sensory and Basal Ganglia Neurons
  evidence:
  - reference: PMID:31903733
    reference_title: "Functional analysis of a novel mutation in the TIMM8A gene that causes deafness-dystonia-optic neuronopathy syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Patient fibroblasts exhibited elongation and/or increased fusion of
      mitochondria, consistent with prior reports.
    explanation: Documents the altered mitochondrial morphology in patient cells.
  - reference: PMID:21984432
    reference_title: "Alterations in expression levels of deafness dystonia protein 1 affect mitochondrial morphology."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Live cell microscopy of primary fibroblasts derived from DDON patients and
      of DDP1 downregulated HeLa cells displayed alterations of mitochondrial
      morphology with notable extensions in the length of mitochondrial tubules
    explanation: >-
      Independent demonstration of the morphology change in both patient cells
      and an engineered knockdown, and the source of the elongation direction.
- name: Neuronal Bioenergetic Failure
  biological_scale: CELLULAR
  description: >-
    A respiratory deficit that is selective for neurons. hTim8a is required for
    complex IV assembly in neuronal cells specifically, through a transient
    interaction with the copper chaperone COX17, and the resulting oxidative
    stress shifts apoptotic regulators so that cells are primed for death.
    Patient iPSC-derived neurons show reduced complex IV level and activity,
    reduced ATP, and increased reactive oxygen species, with CHCHD2
    downregulated as a downstream effector. This is the arm of the mechanism
    that explains why a ubiquitously expressed chaperone produces a disease of
    neurons, and notably it does not require the contested TIM23 step.
  biological_processes:
  - preferred_term: mitochondrial respiratory chain complex IV assembly
    modifier: DECREASED
    term:
      id: GO:0033617
      label: mitochondrial respiratory chain complex IV assembly
  downstream:
  - target: Selective Neurodegeneration of Sensory and Basal Ganglia Neurons
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31682224
      reference_title: "Function of hTim8a in complex IV assembly in neuronal cells provides insight into pathomechanism underlying Mohr-Tranebjærg syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        We hypothesise that enhanced sensitivity of neuronal cells to apoptosis
        is the underlying mechanism of MTS.
      explanation: >-
        The authors' own statement of this edge. Marked as their hypothesis
        rather than a demonstrated step, which is why the node it feeds carries
        separate human neuropathology evidence.
  evidence:
  - reference: PMID:31682224
    reference_title: "Function of hTim8a in complex IV assembly in neuronal cells provides insight into pathomechanism underlying Mohr-Tranebjærg syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We show that hTim8a is required for the assembly of Complex IV in neurons,
      which is mediated through a transient interaction with Complex IV assembly
      factors, in particular the copper chaperone COX17.
    explanation: >-
      Supplies the neuron-selectivity this node asserts: the complex IV
      requirement is specific to neuronal cells, which is why a ubiquitously
      expressed chaperone produces a neuronal disease.
  - reference: PMID:40075073
    reference_title: "CHCHD2 rescues the mitochondrial dysfunction in iPSC-derived neurons from patient with Mohr-Tranebjaerg syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Mitochondrial function analysis revealed reduced protein levels and
      activity of complex IV, diminished ATP synthesis, and increased reactive
      oxygen species (ROS) generation in MTS- and MUT-neurons.
    explanation: >-
      Establishes the bioenergetic deficit in patient-derived neurons against an
      isogenic control.
- name: Selective Neurodegeneration of Sensory and Basal Ganglia Neurons
  biological_scale: TISSUE
  description: >-
    Chronic mitochondrial insufficiency in high-demand post-mitotic neurons
    produces progressive, spatially selective neuronal loss. Human neuropathology
    documents loss in the optic nerve, retina, striate cortex, basal ganglia, and
    dorsal roots of the spinal cord, and near-total loss of cochlear spiral
    ganglion neurons on temporal-bone study. The temporal separation of the
    affected populations is what produces the staged clinical course.
  cell_types:
  - preferred_term: cochlear spiral ganglion neuron
    term:
      id: CL:0011113
      label: spiral ganglion neuron
  - preferred_term: retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  - preferred_term: >-
      striatal neuron (left unbound: the cited neuropathology resolves only to
      basal ganglia and striatum, and does not identify a neuron subclass)
  downstream:
  - target: Auditory Neuropathy
  - target: Dystonia
  - target: Ataxia
  - target: Optic Atrophy
  - target: Dementia
  - target: Personality Change
  - target: Paranoia
  - target: Corticospinal and Bulbar Involvement
  evidence:
  - reference: PMID:11803487
    reference_title: "Neuronal cell death in the visual cortex is a prominent feature of the X-linked recessive mitochondrial deafness-dystonia syndrome caused by mutations in the TIMM8a gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The findings included neuronal cell loss in the optic nerve, retina,
      striate cortex, basal ganglia, and dorsal roots of the spinal cord.
    explanation: >-
      Human neuropathology naming the degenerating populations this node
      asserts.
  - reference: PMID:17471106
    reference_title: Otopathology in Mohr-Tranebjaerg syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      all bones examined showed near-total loss of cochlear neuronal cells and
      severe loss of vestibular neurons. When compared with age-matched
      controls, there was 90% to 95% loss of cochlear neurons and 75% to 85%
      loss of vestibular neurons.
    explanation: >-
      Quantified temporal-bone loss across four affected members of one family,
      establishing the cochlear ganglion degeneration this node asserts.
- name: Corticospinal and Bulbar Involvement
  biological_scale: TISSUE
  description: >-
    Degeneration extending to corticospinal and bulbar pathways, producing
    spasticity and hyperreflexia and, late, the swallowing impairment. Spasticity
    and dysphagia were part of the original DFN-1 description, and the reported
    case shows the spastic and bulbar deficits together. This node is what
    connects dysphagia to the pathograph; the hearing deficit does not cause it.
  downstream:
  - target: Dysphagia
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:8841189
    reference_title: "A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      postlingual progressive sensorineural deafness as the first presenting
      symptom in early childhood, followed by progressive dystonia, spasticity,
      dysphagia, mental deterioration, paranoia and cortical blindness
    explanation: >-
      The original description places spasticity and dysphagia in the syndrome
      and orders them after the deafness, which is the claim this node makes.
  - reference: PMID:37325222
    reference_title: "Case report: Mohr-Tranebjaerg syndrome: hearing impairment as the onset of an insidious disorder with high recurrence risk."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He did not present any motor deficit but had a generalized increase in
      muscle tone, especially in the lower limbs, with moderate spasticity and
      hyperreflexia, with a spastic gait that was impossible without assistance.
    explanation: >-
      Documents the corticospinal signs in the same patient in whom the dysphagia
      appeared.
phenotypes:
- name: Auditory Neuropathy
  category: Neurologic
  description: >-
    Prelingual or postlingual sensorineural hearing impairment beginning in early
    childhood and progressing rapidly to profound loss. The electrophysiologic
    signature is retrocochlear — preserved otoacoustic emissions with absent or
    abnormal auditory brainstem response — reflecting spiral ganglion neuron loss
    rather than a cochlear hair-cell lesion. It is the earliest and most
    consistent manifestation and is near-universal in hemizygous males, but it is
    not obligate: a 2025 report describes a hemizygous adolescent with
    progressive dystonia and basal ganglia iron deposition and no hearing loss at
    all, so a normal audiogram does not exclude the diagnosis.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: auditory neuropathy (retrocochlear sensorineural hearing impairment)
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Males with deafness-dystonia-optic neuronopathy (DDON) syndrome have
      prelingual or postlingual sensorineural hearing impairment in early
      childhood
    explanation: GeneReviews establishes the defining phenotype and its onset.
  - reference: PMID:30634948
    reference_title: "Phenotype prediction of Mohr-Tranebjaerg syndrome (MTS) by genetic analysis and initial auditory neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinically, otological examinations illustrated the typical postsynaptic
      auditory neuropathy for the proband without the symptoms of dystonia or
      optic atrophy. MRI demonstrated abnormal small cochlear symmetric nerves
    explanation: >-
      Documents the auditory-neuropathy pattern and the small cochlear nerves
      that go with a neural lesion.
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The hearing impairment appears to be consistent in age of onset and
      progression, whereas the neurologic, visual, and neuropsychiatric signs
      vary in degree of severity and rate of progression.
    explanation: >-
      Supports treating hearing loss as the consistent anchor of the phenotype
      while the later features vary.
  - reference: PMID:11449109
    reference_title: "Temporal bone histopathologic and genetic studies in Mohr-Tranebjaerg syndrome (DFN-1)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sensorineural hearing loss in Mohr-Tranebjaerg syndrome is the result of a
      postnatal, progressive, severe auditory neuropathy.
    explanation: >-
      States the auditory-neuropathy character of the hearing loss that this
      phenotype's preferred_term asserts and that HP:0000407 alone cannot carry.
  - reference: PMID:40597358
    reference_title: "A novel TIMM8A mutation in Mohr-Tranebjaerg syndrome without hearing loss and with basal ganglia iron deposition."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we report a case of a male adolescent with a previously undescribed
      variant in TIMM8A, associated with progressive dystonia but no hearing
      loss, highlighting the clinical variability of MTS.
    explanation: >-
      Refutes obligate penetrance of the hearing phenotype in hemizygous males.
      Kept as a REFUTE item rather than lowering the frequency, because
      VERY_FREQUENT remains right and the exception is the clinically
      actionable part.
  - reference: PMID:17471106
    reference_title: "Otopathology in Mohr-Tranebjaerg syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We infer that the HL in MTS is likely to be the result of a postnatal and
      progressive degeneration of cochlear neurons and that MTS constitutes a
      true auditory neuropathy.
    explanation: >-
      Independent temporal-bone series reaching the same conclusion, and the
      basis for the management implication carried on the treatment entry.
- name: Dystonia
  category: Neurologic
  description: >-
    Slowly progressive dystonia, often with ataxia, beginning in the teens.
    Progression is highly variable — from minimal symptoms into the thirties to
    rapid loss of ambulation with contractures.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      slowly progressive dystonia or ataxia in the teens
    explanation: GeneReviews gives the phenotype, its course, and its onset decade.
- name: Ataxia
  category: Neurologic
  description: >-
    Progressive ataxia, overlapping in onset with the dystonia and present in a
    subset of affected males.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      slowly progressive dystonia or ataxia in the teens
    explanation: >-
      GeneReviews names ataxia as an alternative to dystonia in the same phase,
      and gives its onset decade.
- name: Optic Atrophy
  category: Ophthalmologic
  description: >-
    Slowly progressive decreased visual acuity from optic atrophy beginning at
    approximately age 20, progressing through central scotomas towards legal
    blindness. The electroretinogram is typically normal, which separates this
    optic neuronopathy from the retinal dystrophy of Usher syndrome.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      slowly progressive decreased visual acuity from optic atrophy beginning at
      approximately age 20 years
    explanation: GeneReviews gives the phenotype and its onset age.
- name: Dementia
  category: Neurologic
  description: Progressive cognitive decline beginning at approximately age 40.
  phenotype_term:
    preferred_term: Dementia
    term:
      id: HP:0000726
      label: Dementia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      dementia beginning at approximately age 40 years
    explanation: GeneReviews gives the phenotype and its onset age.
- name: Personality Change
  category: Psychiatric
  description: >-
    Personality change may appear in childhood and progresses. Aggression and
    psychiatric decompensation requiring hospitalization are reported.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Personality changes
    term:
      id: HP:0000751
      label: Personality changes
    clinical_course: PROGRESSIVE
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Psychiatric symptoms such as personality change and paranoia may appear in
      childhood and progress.
    explanation: >-
      GeneReviews establishes personality change, its childhood onset, and its
      progressive course.
- name: Paranoia
  category: Psychiatric
  description: >-
    Paranoia may appear in childhood alongside personality change and progresses
    with the disease.
  phenotype_term:
    preferred_term: Paranoia
    term:
      id: HP:0011999
      label: Paranoia
    clinical_course: PROGRESSIVE
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Psychiatric symptoms such as personality change and paranoia may appear in
      childhood and progress.
    explanation: >-
      The same GeneReviews sentence names paranoia as a distinct symptom, so it
      is curated separately rather than folded into a generic behavioural term.
- name: Basal Ganglia Iron Accumulation
  category: Neurologic
  description: >-
    Iron deposition in the basal ganglia on brain MRI, reported in a hemizygous
    adolescent who had progressive dystonia and no hearing loss. A single report,
    curated because it is an imaging correlate of the basal ganglia involvement
    the neuropathology describes, and because it appeared in the atypical
    presentation that most challenges the diagnostic pattern.
  phenotype_term:
    preferred_term: Iron accumulation in brain
    term:
      id: HP:0012675
      label: Iron accumulation in brain
  evidence:
  - reference: PMID:40597358
    reference_title: "A novel TIMM8A mutation in Mohr-Tranebjaerg syndrome without hearing loss and with basal ganglia iron deposition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 16-year-old male was referred for genetic evaluation due to a 6-year
      history of progressive dystonia, motor coordination difficulties, and iron
      deposits in the basal ganglia detected by brain MRI.
    explanation: Reports the imaging finding this phenotype records.
- name: Dysphagia
  category: Gastrointestinal
  description: >-
    Late-stage swallowing impairment carrying aspiration risk; severe cases have
    required percutaneous gastrostomy.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:37325222
    reference_title: "Case report: Mohr-Tranebjaerg syndrome: hearing impairment as the onset of an insidious disorder with high recurrence risk."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Severe dysphagia was present during the following weeks after the
      encephalopathic period, and percutaneous gastrostomy was needed but removed
      in less than a year.
    explanation: Documents dysphagia severe enough to require gastrostomy.
histopathology:
- name: Cochlear and Vestibular Ganglion Neuronal Loss
  description: >-
    Temporal-bone study shows near-complete loss of cochlear ganglion neurons
    with severe loss of vestibular neurons, while the hair cells of both organs
    and the geniculate and trigeminal ganglia are preserved — so the
    degeneration is selective, not a general ganglion-cell loss. The vestibular
    loss is largely clinically silent.
  evidence:
  - reference: PMID:11449109
    reference_title: Temporal bone histopathologic and genetic studies in Mohr-Tranebjaerg syndrome (DFN-1).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was near complete loss of spiral ganglion cells with loss of nearly
      all peripheral and central processes. Only 1,765 spiral ganglion cells
      remained (8.5% of mean normal for age). The organ of Corti (including hair
      cells), stria vascularis, and spiral ligament were preserved.
    explanation: >-
      The decisive observation for this entry: the ganglion is destroyed while
      the organ of Corti and its hair cells are preserved, which is what makes
      the lesion retrocochlear rather than cochlear.
  - reference: PMID:11449109
    reference_title: Temporal bone histopathologic and genetic studies in Mohr-Tranebjaerg syndrome (DFN-1).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was also a severe loss of Scarpa's ganglion cells with preservation
      of vestibular hair cells. The population of geniculate and trigeminal
      ganglion cells appeared normal.
    explanation: >-
      Documents the vestibular ganglion loss and shows the degeneration is
      selective rather than a general ganglion-cell loss.
  - reference: PMID:17471106
    reference_title: Otopathology in Mohr-Tranebjaerg syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      When compared with age-matched controls, there was 90% to 95% loss of
      cochlear neurons and 75% to 85% loss of vestibular neurons.
    explanation: Quantifies the loss across four affected individuals.
  - reference: PMID:30634948
    reference_title: "Phenotype prediction of Mohr-Tranebjaerg syndrome (MTS) by genetic analysis and initial auditory neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      while the vestibular function appeared to be less influenced
    explanation: >-
      Supports the clinical-silence half of this node: the vestibular ganglion is
      severely depleted histologically yet function testing is relatively spared,
      which is why vestibular involvement is recorded here and not as a
      phenotype.
- name: Multifocal Central Neuronal Loss
  description: >-
    Neuronal loss in the optic nerve, retina, striate cortex, basal ganglia, and
    dorsal roots of the spinal cord in affected males from two unrelated families
    carrying different TIMM8A mutations.
  evidence:
  - reference: PMID:11803487
    reference_title: "Neuronal cell death in the visual cortex is a prominent feature of the X-linked recessive mitochondrial deafness-dystonia syndrome caused by mutations in the TIMM8a gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The findings included neuronal cell loss in the optic nerve, retina,
      striate cortex, basal ganglia, and dorsal roots of the spinal cord.
    explanation: Direct human neuropathologic description.
genetic:
- name: TIMM8A
  gene_term:
    preferred_term: TIMM8A
    term:
      id: hgnc:11817
      label: TIMM8A
  inheritance:
  - name: X-linked recessive
    inheritance_term:
      preferred_term: X-linked recessive inheritance
      term:
        id: HP:0001419
        label: X-linked recessive inheritance
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:31903733
    reference_title: "Functional analysis of a novel mutation in the TIMM8A gene that causes deafness-dystonia-optic neuronopathy syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The TIMM8A gene product localizes to the intermembrane space in
      mitochondria where it functions in the import of nuclear-encoded proteins
      into the mitochondrial inner membrane. Frameshifts or premature stops
      represent the majority of mutations in TIMM8A that cause DDON syndrome.
    explanation: Establishes the gene product's localization, function, and variant spectrum.
  - reference: PMID:40075073
    reference_title: "CHCHD2 rescues the mitochondrial dysfunction in iPSC-derived neurons from patient with Mohr-Tranebjaerg syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The human TIMM8A gene consists of one intron and two exons, encoding
      a 97-amino acid protein, TIMM8a/DDP1, which is located in the
      intermembrane space (IMS) of mitochondria
    explanation: Gives the gene structure and protein size stated in this entry.
diagnosis:
- name: Auditory Neuropathy Electrophysiologic Signature
  description: >-
    Preserved otoacoustic emissions with absent or abnormal auditory brainstem
    response and absent stapedial reflex, in a structurally normal inner ear, in
    a male with early-onset hearing loss. Because this pattern separates a neural
    from a hair-cell lesion, it is the practical entry point to the diagnosis and
    the reason TIMM8A belongs on auditory-neuropathy sequencing panels.
  evidence:
  - reference: PMID:30634948
    reference_title: "Phenotype prediction of Mohr-Tranebjaerg syndrome (MTS) by genetic analysis and initial auditory neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Furthermore, we found another two TIMM8A variations, the deletion
      c.133_135delGAG and a copy number variation (CNV) including the TIMM8A
      gene, in two independent case, when we performed NGS on an auditory
      neuropathy population.
    explanation: >-
      Shows TIMM8A variants being recovered by sequencing an auditory-neuropathy
      cohort, which is what makes this signature diagnostically useful.
  - reference: PMID:11449109
    reference_title: "Temporal bone histopathologic and genetic studies in Mohr-Tranebjaerg syndrome (DFN-1)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sensorineural hearing loss in Mohr-Tranebjaerg syndrome is the result of a
      postnatal, progressive, severe auditory neuropathy.
    explanation: >-
      Establishes the auditory-neuropathy character of the deficit that the
      electrophysiologic signature in this node detects.
  - reference: PMID:30634948
    reference_title: "Phenotype prediction of Mohr-Tranebjaerg syndrome (MTS) by genetic analysis and initial auditory neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MRI demonstrated abnormal small cochlear symmetric nerves
    explanation: >-
      Qualifies this node's "structurally normal inner ear" framing: the
      labyrinth is normal, but the cochlear nerves themselves may be visibly
      small, which is itself consistent with a neural rather than cochlear
      lesion.
- name: Molecular Testing Including Deletion Analysis
  description: >-
    Sequence analysis of TIMM8A detects roughly half of cases; the remainder are
    contiguous Xq22.1 deletions that require deletion/duplication analysis or
    chromosomal microarray. Sequence-only testing therefore misses about half of
    affected individuals, and microarray is specifically indicated where
    co-occurring agammaglobulinemia suggests a BTK-spanning deletion.
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The diagnosis of DDON syndrome is established in either a male proband who
      has a hemizygous TIMM8A pathogenic variant (~50% of affected males) or a
      female proband who has a heterozygous TIMM8A pathogenic variant (~50% of
      affected females) or a contiguous gene deletion of Xq22.1 involving TIMM8A
      (~50% of affected males and females)
    explanation: >-
      GeneReviews gives the split between sequence-detectable and
      deletion-detectable cases.
differential_diagnoses:
- name: Usher syndrome
  description: >-
    Also combines deafness with progressive visual loss, but the visual lesion is
    a retinal dystrophy with an abnormal electroretinogram, whereas DDON has optic
    atrophy with a typically normal electroretinogram.
- name: Wolfram syndrome
  description: >-
    Also combines hearing loss with optic atrophy, but is distinguished by
    juvenile-onset diabetes mellitus and the absence of dystonia.
- name: MEGDEL syndrome
  description: >-
    SERAC1-related deafness-dystonia, distinguished by Leigh-like MRI features
    and 3-methylglutaconic aciduria.
- name: Arts syndrome
  description: >-
    PRPS1-related X-linked disorder in which hearing loss predominates without
    the dystonia of DDON.
treatments:
- name: Cochlear Device Implantation
  description: >-
    Cochlear implantation is attempted and has been performed in DDON, but
    benefit is variable and generally less than in hair-cell sensorineural
    deafness. The reason is specific and follows from the pathograph: an implant
    works by bypassing the hair cells and electrically stimulating the spiral
    ganglion neurons directly, and in this disease those neurons are the
    population that has degenerated - 8.5% of the age-normal count remained in
    the case with a cytocochleogram, in an ear whose organ of Corti and hair
    cells were preserved. The device's target is what the disease destroys,
    which is the opposite of the usual indication.
  treatment_term:
    preferred_term: cochlear device implantation
    term:
      id: NCIT:C15329
      label: Surgical Procedure
    qualifiers:
    - predicate:
        preferred_term: medical device
        term:
          id: NCIT:C16830
          label: Medical Device
      value:
        preferred_term: cochlear implant
        term:
          id: NCIT:C157820
          label: Cochlear Implant
  therapeutic_modality: DEVICE
  target_mechanisms:
  - target: Auditory Neuropathy
    description: >-
      Addresses the hearing phenotype symptomatically. It cannot restore the
      spiral ganglion neurons it depends on for stimulation, which is why
      benefit is limited and variable.
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: >-
      Because auditory neuronopathy is the cause of the hearing loss, hearing
      aids have only variable success.
    explanation: >-
      GeneReviews states the mechanistic principle - the neural basis of the
      loss limits what a peripheral device achieves. Graded INDIRECT because it
      is stated of hearing aids, and this entry applies it to implantation.
  - reference: PMID:31903733
    reference_title: "Functional analysis of a novel mutation in the TIMM8A gene that causes deafness-dystonia-optic neuronopathy syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      at age 6 years received cochlear implants
    explanation: >-
      Establishes that implantation is actually performed in this disease, which
      the GeneReviews hearing-aid statement does not.
  - reference: PMID:11449109
    reference_title: "Temporal bone histopathologic and genetic studies in Mohr-Tranebjaerg syndrome (DFN-1)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Only 1,765 spiral ganglion cells remained (8.5% of mean normal for age).
      The organ of Corti (including hair cells), stria vascularis, and spiral
      ligament were preserved.
    explanation: >-
      Quantifies the depletion of the exact neuronal population a cochlear
      implant stimulates, which is the mechanistic basis for the limited
      benefit this entry describes.
- name: Physical and Occupational Therapy
  description: >-
    Physical medicine and rehabilitation to improve fine and gross motor skills
    and mobility, prevent contractures, and provide adaptive devices for
    activities of daily living.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  therapeutic_modality: BEHAVIORAL
  target_mechanisms:
  - target: Dystonia
    description: Symptomatic management of the movement disorder and its complications.
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Physical medicine and rehabilitation, physical and occupational therapy to
      improve fine and gross motor skills and mobility, to prevent contractures,
      and to provide adaptive devices to improve activities of daily living.
    explanation: GeneReviews management recommendation for the motor phenotype.
- name: Genetic Counseling
  description: >-
    Counseling for carrier females. The chance of transmitting the variant is
    50% per pregnancy, which is not the same as a 50% chance of an affected
    child: sons who inherit it are affected, while daughters who inherit it are
    heterozygotes who may have only mild hearing impairment and focal dystonia.
    Prenatal and preimplantation testing are available once the familial variant
    is known. The 2023 four-affected-male family report makes the case that
    timely etiologic investigation of childhood hearing loss is what brings this
    within reach.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:37325222
    reference_title: "Case report: Mohr-Tranebjaerg syndrome: hearing impairment as the onset of an insidious disorder with high recurrence risk."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recurrence risk is high for female carriers, and reproductive options
      should be offered.
    explanation: Directly supports counseling as a management component.
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      the chance of transmitting the genetic alteration in each pregnancy is 50%
    explanation: >-
      The source of the quantitative recurrence risk this treatment states. The
      case report cited above says only that the risk is high.
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Prenatal diagnosis for a pregnancy at increased risk and preimplantation
      genetic testing are possible if the DDON-causing genetic alteration in the
      family is known.
    explanation: >-
      Supports the reproductive-testing options named here, including the
      condition that the familial variant must already be identified.
- name: Antioxidant Rescue (preclinical only)
  description: >-
    Not a clinical treatment, and recorded here as the only pharmacological lead
    in the cited literature. In neuronal cells lacking hTim8a the complex IV
    assembly defect produces oxidative stress that primes the cells for
    apoptosis, and relieving that stress with vitamin E rescues them. This is a
    cell-culture result with no human evidence in DDON; it is curated so the lead
    is findable, not to imply a therapy.
  treatment_term:
    preferred_term: antioxidant supplementation (investigational, cell models only)
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: vitamin E
      term:
        id: CHEBI:33234
        label: vitamin E
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Neuronal Bioenergetic Failure
    description: >-
      Acts on the oxidative-stress consequence of the complex IV assembly defect,
      not on the assembly defect itself.
  evidence:
  - reference: PMID:31682224
    reference_title: "Function of hTim8a in complex IV assembly in neuronal cells provides insight into pathomechanism underlying Mohr-Tranebjærg syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Alleviation of oxidative stress with Vitamin E treatment rescues cells from
      apoptotic vulnerability.
    explanation: >-
      The rescue result this entry records. In vitro only, which is why the
      treatment is labelled preclinical.
- name: Supportive and Multidisciplinary Care
  description: >-
    There is no disease-modifying therapy. Management is supportive: standard
    treatment of psychiatric issues, deaf-blind service referral and tactile sign
    language as vision loss compounds the deafness, feeding support for
    dysphagia, and surveillance. The surveillance quoted below is neurologic,
    developmental, speech-language and vision assessment plus physical and
    occupational therapy review; audiologic follow-up is standard practice in a
    disease whose presenting feature is hearing loss, but it is not part of the
    GeneReviews surveillance recommendation and is not claimed as one here.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Educational programs for developmental and sensory deficits, including
      training in tactile sign language.
    explanation: GeneReviews management recommendation for combined sensory loss.
  - reference: PMID:20301395
    reference_title: "Deafness-Dystonia-Optic Neuronopathy Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Regular neurologic evaluation and assessment for dementia and/or
      psychiatric manifestations; annual developmental, speech-language, and
      vision assessments in childhood
    explanation: >-
      Supports the surveillance this treatment describes, which was previously
      asserted without a quoted source.
animal_models:
- name: Timm8a1 I23fs49X frameshift mouse
  species: Mouse
  genotype: Timm8a1 p.I23fs49X hemizygous (CRISPR/Cas9)
  publication: PMID:32820032
  description: >-
    A CRISPR/Cas9 knock-in mouse carrying a frameshift in the murine ortholog,
    generated alongside the characterization of a family carrying a novel
    hemizygous DDP1 variant.
  modeled_mechanisms:
  - target: Mitochondrial Morphology and Dynamics Disturbance
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Mutant mice show abnormal mitochondrial structure in several brain areas,
      quantified in hippocampus as reduced mitochondrial size with upregulated
      Mtfp1/Mtp18, alongside hearing impairment and cognitive deficit.
    limitations: >-
      The direction differs from the human cell result: mouse hippocampal
      mitochondria are smaller, whereas patient fibroblasts and knockdown HeLa
      cells show elongation. The node is scoped to dysregulated dynamics rather
      than a direction for this reason, but a reader should not take the mouse
      as evidence for the human direction. The mouse also shows the organelle
      change without frank hippocampal neuronal loss, so it models this node and
      not the degeneration downstream of it.
    evidence:
    - reference: PMID:32820032
      reference_title: "Frameshift mutation of Timm8a1 gene in mouse leads to an abnormal mitochondrial structure in the brain, correlating with hearing and memory impairment."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Electron microscopic analysis of brain samples from the mutant mice
        indicated abnormal mitochondrial structure in several brain areas.
      explanation: Supports the model as informative for the mitochondrial phenotype.
    readouts:
    - name: Mitochondrial ultrastructure in brain
      target: Mitochondrial Morphology and Dynamics Disturbance
      direction: ALTERED
      interpretation: >-
        Electron-microscopic correlate of the mitochondrial arm of this node in
        the mouse.
      evidence:
      - reference: PMID:32820032
        reference_title: "Frameshift mutation of Timm8a1 gene in mouse leads to an abnormal mitochondrial structure in the brain, correlating with hearing and memory impairment."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Electron microscopic analysis of brain samples from the mutant mice
          indicated abnormal mitochondrial structure in several brain areas.
        explanation: Reports the ultrastructural measurement behind this readout.
    - name: Hippocampal mitochondrial size and Mtfp1/Mtp18 level
      target: Mitochondrial Morphology and Dynamics Disturbance
      direction: DECREASED
      interpretation: >-
        Mitochondrial size falls without frank neuronal loss, and the reduction
        tracks upregulation of the fission factor Mtfp1/Mtp18. In this model the
        organelle phenotype therefore precedes, rather than follows, neuronal
        death.
      evidence:
      - reference: PMID:36090790
        reference_title: "Reduced mitochondrial size in hippocampus and psychiatric behavioral changes in the mutant mice with homologous mutation of Timm8a1-I23fs49X."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Although the general neuronal loss was not found in the hippocampus of
          the MUT genotype, EM assessment indicated that the mitochondrial size
          showing as aspect ratio and form factor in the hippocampus of the MUT
          strain was significantly reduced compared to that in the WT genotype.
        explanation: >-
          Reports the quantitative measurement behind this readout, and is the
          primary source for the mitochondrial-size finding.
      - reference: PMID:36090790
        reference_title: "Reduced mitochondrial size in hippocampus and psychiatric behavioral changes in the mutant mice with homologous mutation of Timm8a1-I23fs49X."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          this phenomenon was correlated with the upregulation of translation of
          mitochondrial fission process protein 1(Mtfp1)/mitochondrial 18 kDa
          protein (Mtp18), a key fission factor
        explanation: Identifies the fission factor this readout names.
  - target: Impaired Intermembrane-Space Escort of Hydrophobic Precursors
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    model_scale: MOLECULAR
    description: >-
      The mouse does not reproduce the TIM23 import defect that the human and
      yeast biochemistry places at the centre of the mechanism.
    limitations: >-
      Tim23 and Tom40 import and oxidative-phosphorylation biogenesis were all
      unaffected in the mutant mouse. This is the substantive negative result of
      the model: the animal has the disease-relevant hearing and cognitive
      phenotypes without the import lesion, so either the murine ortholog is
      functionally redundant for this step or the import defect is not the whole
      mechanism in vivo.
    evidence:
    - reference: PMID:32820032
      reference_title: "Frameshift mutation of Timm8a1 gene in mouse leads to an abnormal mitochondrial structure in the brain, correlating with hearing and memory impairment."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        However, Timm8a1I23fs49X/y mutation did not affect the import of
        mitochondria inner member protein Tim23 and outer member protein Tom40 as
        well as the biogenesis of the proteins in the mitochondrial oxidative
        phosphorylation system and the manganese superoxide dismutase (MnSOD /
        SOD-2).
      explanation: >-
        Supports this FAILS_TO_RECAPITULATE link: the assay was done and
        reported negative, so the quote establishes the failure the link
        asserts. It contradicts the import account, not the link.
  evidence:
  - reference: PMID:32820032
    reference_title: "Frameshift mutation of Timm8a1 gene in mouse leads to an abnormal mitochondrial structure in the brain, correlating with hearing and memory impairment."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The male mice with Timm8a1I23fs49X/y mutant exhibited less weight gain,
      hearing impairment and cognitive deficit.
    explanation: >-
      Establishes that the model reproduces the cardinal auditory and cognitive
      phenotypes, which is what makes it informative despite the import result.
experimental_models:
- name: MTS patient iPSC-derived neurons with isogenic CRISPR control
  experimental_model_type: IPSC_DERIVED_MODEL
  description: >-
    iPSCs from a male MTS patient carrying TIMM8A c.225-229del (p.Q75fs95*),
    differentiated into neurons and compared against both a healthy control line
    and an isogenic control into which the same mutation was introduced by
    CRISPR/Cas9. The isogenic arm is what lets the neuronal phenotype be
    attributed to the variant rather than to line background.
  publication: PMID:40075073
  modeled_mechanisms:
  - target: Neuronal Bioenergetic Failure
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: CELLULAR
    description: >-
      Patient and isogenic-mutant neurons both show reduced complex IV level and
      activity, reduced ATP, increased reactive oxygen species, and mitochondrial
      fragmentation, with impaired neuronal differentiation.
    limitations: >-
      A cell model cannot report the staged, decades-long selectivity of the
      human disease across auditory, basal ganglia, and visual populations.
    evidence:
    - reference: PMID:40075073
      reference_title: "CHCHD2 rescues the mitochondrial dysfunction in iPSC-derived neurons from patient with Mohr-Tranebjaerg syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Mitochondrial function analysis revealed reduced protein levels and
        activity of complex IV, diminished ATP synthesis, and increased reactive
        oxygen species (ROS) generation in MTS- and MUT-neurons.
      explanation: Supports this human cell model as informative for the node.
    readouts:
    - name: Complex IV protein level and activity
      target: Neuronal Bioenergetic Failure
      direction: DECREASED
      interpretation: Bioenergetic correlate of the neuronal mitochondrial deficit.
      evidence:
      - reference: PMID:40075073
        reference_title: "CHCHD2 rescues the mitochondrial dysfunction in iPSC-derived neurons from patient with Mohr-Tranebjaerg syndrome."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Mitochondrial function analysis revealed reduced protein levels and
          activity of complex IV, diminished ATP synthesis, and increased
          reactive oxygen species (ROS) generation in MTS- and MUT-neurons.
        explanation: Reports the complex IV measurement behind this readout.
    - name: CHCHD2 rescue of neurite outgrowth
      target: Neuronal Bioenergetic Failure
      direction: RESTORED
      interpretation: >-
        Overexpressing CHCHD2 reverses the mitochondrial and neurite phenotype,
        placing CHCHD2 downstream of TIMM8a loss.
      evidence:
      - reference: PMID:40075073
        reference_title: "CHCHD2 rescues the mitochondrial dysfunction in iPSC-derived neurons from patient with Mohr-Tranebjaerg syndrome."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Overexpression of CHCHD2 rescued mitochondrial dysfunction and promoted
          neurite elongation in MTS-neurons, suggesting that CHCHD2 acts as a
          downstream effector of TIMM8a in the pathogenesis of MTS.
        explanation: Reports the rescue measurement behind this readout.
- name: MTS patient dermal fibroblasts
  experimental_model_type: PRIMARY_CELL_CULTURE
  description: >-
    Patient fibroblasts carrying C66W or p.Met1Leu, used to show absence of
    TIMM8a protein, reduced steady-state TIMM13, and altered mitochondrial
    morphology.
  publication: PMID:31903733
  modeled_mechanisms:
  - target: TIM8-TIM13 Chaperone Complex Assembly Failure
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: MOLECULAR
    description: >-
      Directly demonstrates loss of DDP1 and the commensurate fall in its
      obligate partner in patient-derived cells.
    limitations: >-
      Fibroblasts are not an affected cell type in this disease, so they report
      the molecular lesion but not the neuron-selective consequence.
    evidence:
    - reference: PMID:31903733
      reference_title: "Functional analysis of a novel mutation in the TIMM8A gene that causes deafness-dystonia-optic neuronopathy syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        We observed a commensurate decrease in the steady-state level of the
        Tim13 protein (the binding partner of Tim8a) but no decrease in TIMM13
        transcripts.
      explanation: Supports the fibroblast model as informative for complex assembly.
discussions:
- discussion_id: timm8a_tim23_import_in_vivo
  kind: HUMAN_MODEL_MISMATCH
  attaches_to:
  - pathophysiology#Impaired Intermembrane-Space Escort of Hydrophobic Precursors
  prompt: >-
    Is impaired TIM23 import actually the operative lesion, given that patient
    fibroblasts, RNAi knockdown cells and the Timm8a1 mutant mouse all fail to
    show the import or respiratory defect that patient lymphoblasts do?
  rationale: >-
    This is not a clean species gap, and the entry should not be read as one.
    The disagreement is already present within human patient cells. Patient
    lymphoblasts carrying DDP1-Q34X showed decreased NADH and defects in
    mitochondrial protein import (PMID:15254020), while RNAi knockdown and
    patient fibroblasts showed no effect on respiration or membrane potential
    and the TIM23 account was framed there as a proposal (PMID:21984432). The
    mouse then sides with the negative result: Tim23 and Tom40 import and
    oxidative-phosphorylation biogenesis were assayed in the Timm8a1 mutant and
    reported unaffected (PMID:32820032), and the same group states in the
    follow-up that "we and others did not find Tim8a to mediate the biogenesis
    of Tim23" (PMID:36090790). PMID:40075073 calls the human mechanism
    controversial outright.

    So the honest reading is a contested step, not a species artifact, and the
    contest may be about cell type rather than about the biochemistry: the
    positive result is in a lymphoid line, the negatives are in fibroblasts,
    HeLa and whole mouse brain, and none of those is an affected cell type. Two
    alternative accounts have their own support and do not require TIM23
    depletion: neuron-specific complex IV assembly through COX17
    (PMID:31682224), and loss of the citrin/aralar1 aspartate-glutamate
    carriers, whose expression is prominent in large brain neurons
    (PMID:15254020). The distinction matters practically, because CHCHD2 is
    currently the only node in this entry with a demonstrated rescue.
  proposed_experiments:
  - experiment_id: tim23_import_in_patient_neurons
    name: Assay TIM23 steady-state level and import in patient-derived neurons
    description: >-
      Every result on either side of this contradiction comes from a cell type
      the disease spares: lymphoblasts, fibroblasts, HeLa, and whole mouse
      brain. The MTS patient iPSC-derived neurons with an isogenic CRISPR
      control already exist (PMID:40075073), so measuring TIM23 import and
      steady-state level in them would test the step for the first time in the
      cell type that actually degenerates, and would discriminate a cell-type
      explanation of the disagreement from a straightforwardly wrong mechanism.
    readouts:
    - name: TIM23 steady-state level in patient-derived neurons
      target: pathophysiology#Impaired Intermembrane-Space Escort of Hydrophobic Precursors
      direction: DECREASED
      interpretation: >-
        A reduction in the human neuronal context would support the import
        account; an unchanged level would align the human neuron with the mouse
        and move the mechanism onto the CHCHD2/complex IV arm.
    would_support:
    - pathophysiology#Impaired Intermembrane-Space Escort of Hydrophobic Precursors
    supporting_outcome:
    - >-
      Reduced TIM23 steady-state level and impaired import in patient
      iPSC-derived neurons relative to the isogenic control.
    refuting_outcome:
    - >-
      TIM23 import and steady-state level indistinguishable from the isogenic
      control, as in the mutant mouse, despite the complex IV and CHCHD2
      phenotype being present.
notes: >-
  Naming: MONDO labels this concept "deafness dystonia syndrome", which is used
  for disease_term, while the entry name follows the GeneReviews title. The
  eponym Mohr-Tranebjaerg syndrome is what the clinical literature uses almost
  exclusively. Jensen syndrome (MIM 311150) was described separately and was
  shown to be allelic when a TIMM8a stop mutation was found segregating in the
  original Danish family, so it is carried here as a synonym rather than as a
  separate entry.

  The vestibular ganglion is severely affected histologically while vestibular
  function testing is relatively spared, so the vestibular involvement is
  recorded under histopathology and deliberately not curated as a phenotype.

  Term notes, so they are not re-litigated. HPO has no term for auditory
  neuropathy, so the hearing phenotype is bound to HP:0000407 Sensorineural
  hearing impairment with the neural character carried in preferred_term and in
  the description; HP:0011971, which is easy to reach for by name, is
  Dermatographic urticaria. The striatal cell type in the neurodegeneration node
  is left unbound because the neuropathology resolves only to basal ganglia and
  striatum, and binding a neuron subclass such as medium spiny neuron would
  assert a specificity no cited source supports.
📚

References & Deep Research

References

1
PMID:20301395
Deafness-Dystonia-Optic Neuronopathy Syndrome.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Review round: correct a false prevalence note, put the 50% recurrence risk on GeneReviews · 2026-09-07T21:34:22Z · View source

Post-approval round on PR #11393. The reviewer approved with no blocking findings and four optional suggestions; this round takes two of them and fixes a defect of my own that the suggestions surfaced. The defect: prevalence.notes claimed the diagnostic-yield figure from the auditory-neuropathy sequencing cohort "is recorded on the diagnosis section instead". It was not recorded anywhere in the entry, and checking the cache showed why - the 3/168 figure and the 1.8% derived from it appear only in the deep-research report, not in the cached abstract of PMID:30634948, so the figure was never quotable in the first place. That is prose making a false claim about the entry's own contents, which is the failure mode CLAUDE.md warns about under "prose describing repository state is content, and it rots". The note now says the figure exists in the report, is absent from the cached abstract, is therefore not curated here, and that the diagnosis section quotes the cohort finding qualitatively. Reviewer suggestion 1 taken: the Genetic Counseling treatment asserted a 50% per-pregnancy recurrence risk and the availability of prenatal and preimplantation testing, but cited only PMID:37325222's weaker "Recurrence risk is high for female carriers". Both exact GeneReviews sentences were already in references_cache/PMID_20301395.md and are now quoted, so the quantitative claim sits on the source that actually makes it. The case-report item is kept alongside rather than replaced, since it supports counseling as a management component. Reviewer suggestion 2 taken: the surveillance described on Supportive and Multidisciplinary Care was asserted without a quoted source. The GeneReviews surveillance sentence is now quoted. Reviewer suggestion 3 not taken, and the reason is the defect above: the figure is not quotable from any cached reference, so there is nothing to put on the diagnosis node. The corrected prevalence note now says this explicitly rather than pointing at a figure that is not there. Reviewer suggestion 4 not taken. The reviewer identified it as non-blocking on the grounds that none of the four items (peripheral sensory neuropathy, recurrent aspiration pneumonia, the STAM1 trafficking role, symptomatic dystonia pharmacotherapy) has a quotable exact snippet in a cached reference, and that the research itself labels the dystonia drugs "not MTS-specific". I agree; adding them would mean either fetching new references for claims the entry does not need or writing unsourced content. This push costs the existing approval, since main has dismiss_stale_reviews enabled. That was weighed: the entry carried a statement that was factually wrong about itself and would otherwise have merged that way, and the two citation improvements ride along in the same push rather than as a separate chore commit. Validation after the change: just validate and just validate-disorders both pass, 78/78 snippets verified (up from 75/75). check-entity-refs, check-causal-targets, check-duplicate-keys, check-enum-values, check-snippet-grading, check-title-snippets, check-snippet-length, check-folded-hyphens and check-reference-titles all OK. No new references were fetched; every snippet added here comes from PMID_20301395.md, which was already committed.

Create: Deafness-Dystonia-Optic Neuronopathy Syndrome · 2026-09-04T21:42:22Z · View source

New entry created from the stubs/ queue under claim issue #11025. The stub is deleted in the same PR. Deep research: one run, provider claude_code (research/Deafness-Dystonia-Optic_Neuronopathy_Syndrome-deep-research-claude_code.md). No other provider was reachable in this environment: EDISON_API_KEY, FUTUREHOUSE_API_KEY, ASTA_API_KEY, OPENSCIENTIST_API_KEY, PERPLEXITY_API_KEY and OPENAI_API_KEY were all unset, and claude_code auto-enables from the claude CLI on PATH. The report's reference validation came back 22/22 verified, confabulation_rate 0.0, no unresolved references. Its term validation set needs_review true and named two mislabelled UBERON bindings, which were NOT used: UBERON:0001846 is internal ear, not spiral ganglion, and UBERON:0009713 is endocardium of left ventricle, not vestibular ganglion. The spiral ganglion concept was bound instead to CL:0011113 (spiral ganglion neuron), verified via OLS. GeneReviews baseline: PMID:20301395 was found, fetched, tagged GeneReviews in the top-level references block, and used as the phenotype baseline. Every phenotype in its Clinical Characteristics paragraph is curated (hearing impairment, dystonia/ataxia, optic atrophy, dementia, psychiatric symptoms), plus dysphagia from PMID:37325222. Its management statement that "Because auditory neuronopathy is the cause of the hearing loss, hearing aids have only variable success" is quoted on the cochlear implantation treatment. That is the organizing idea of the entry: the treatment expectation follows from the retrocochlear lesion in the pathograph rather than sitting beside it. Pathophysiology is a five-node causal chain with cited downstream edges: TIMM8A loss of function -> TIM8-TIM13 complex assembly failure -> impaired intermembrane-space escort of hydrophobic precursors -> neuronal mitochondrial dysfunction -> selective neurodegeneration, fanning out to the four clinical phenotypes. A substantive negative result is curated rather than smoothed over. The Timm8a1 I23fs49X mouse (PMID:32820032) reproduces hearing impairment and cognitive deficit but explicitly did NOT show the Tim23/Tom40 import defect or any oxidative-phosphorylation biogenesis defect. That is recorded as a FAILS_TO_RECAPITULATE modeled_mechanisms link carrying supports REFUTE evidence against the import node, and as a HUMAN_MODEL_MISMATCH discussion with a proposed experiment to assay TIM23 in patient iPSC-derived neurons. PMID:40075073 independently calls the human cross-membrane transport mechanism controversial, so the entry carries both readings instead of asserting the textbook one. Two references beyond the report's narrative were added after reading the cache the report's own validation had populated, and both change a claim. PMID:31682224 shows hTim8a is required for complex IV assembly specifically in neurons via COX17, with the resulting oxidative stress priming cells for apoptosis. That is the neuron-selectivity step; without it the entry asserted a neuronal disease from a ubiquitously expressed chaperone with no cited bridge. PMID:36090790 is the correct primary source for the reduced hippocampal mitochondrial size and the Mtfp1/Mtp18 upregulation. The deep-research report attributed that finding to PMID:32820032, which is the earlier paper in the same series and does not report it; the readout is cited to PMID:36090790 accordingly. Two ontology label corrections, both caught before binding. HP:0011971 is Dermatographic urticaria, not Auditory neuropathy as assumed on the first pass; HPO has no auditory neuropathy term, so HP:0000407 Sensorineural hearing impairment is bound with the specificity carried in preferred_term. HP:0000708 is Atypical behavior, not Behavioral abnormality as the report labelled it. Secondary-citation defect found and fixed during self-review, before any PR. The cochlear/vestibular ganglion loss was first cited to PMID:40075073, but that sentence sits in the iPSC paper's introduction summarizing its own reference [8] - it is not that paper's finding. It was replaced with the primary temporal-bone sources, PMID:11449109 (single case: near-complete spiral ganglion loss, only 8.5% of age-normal cells remaining, with the organ of Corti including hair cells preserved) and PMID:17471106 (four members of one Norwegian family: 90-95% cochlear and 75-85% vestibular neuron loss). This matters beyond citation hygiene: the hair-cell-sparing observation in PMID:11449109 is the direct evidence that the lesion is retrocochlear, which is the claim the whole entry, and its treatment reasoning, rests on. Both papers' auditory-neuropathy conclusions were also added to the hearing phenotype. Adversarial self-review before opening the PR (a subagent with fresh context, per the curate skill's red-team step) found several things the validators cannot see, all fixed in this same commit rather than deferred. An exact-quote violation that no gate catches: a folded YAML scalar wrapped "97-amino acid" as "97\n-amino acid", which resolves to "97 -amino acid" and is not a substring of the source. check_folded_hyphens.py only matches a hyphen at the END of a folded line (EOL_HYPHEN_RE = [A-Za-z0-9]-$), so the mirror-image case of a leading hyphen on the next line passes it. The snippet was rewrapped. The checker gap is real and worth its own issue; it is not fixed here. A secondary-citation defect, described above, where the cochlear ganglion loss was cited to an iPSC paper's introduction. Replaced with PMID:11449109 and PMID:17471106. An anatomical error in the cochlear-implant treatment. The entry had said an implant "stimulating distal to the loss cannot bypass" the spiral ganglion lesion. That is backwards: an implant bypasses the hair cells and stimulates the spiral ganglion neurons directly, so in DDON its target population is precisely the one that has degenerated. Rewritten, and evidenced with the 8.5%-of-normal spiral ganglion count from PMID:11449109 plus a documented implantation from PMID:31903733, because the only prior evidence was a GeneReviews sentence about hearing aids. The HUMAN_MODEL_MISMATCH was reframed. It had been written as a human-versus-mouse species gap. Reading the primary literature shows the disagreement is already inside human patient cells: patient lymphoblasts show an import defect and decreased NADH (PMID:15254020), while patient fibroblasts and RNAi knockdown show no effect on respiration or membrane potential and frame the TIM23 account as a proposal (PMID:21984432); the mouse then sides with the negative. Both primaries were fetched and cited, the import node now carries REFUTE items alongside its SUPPORT items, and the discussion rationale states the contest and notes that every result on either side comes from a cell type the disease spares. Two alternative accounts that do not require TIM23 depletion are named: neuron-specific complex IV assembly via COX17 (PMID:31682224) and loss of the citrin/aralar1 carriers (PMID:15254020). A false causal edge was removed: Auditory Neuropathy had Dysphagia as a sequela, asserting the hearing deficit causes the swallowing deficit. It does not. A Corticospinal and Bulbar Involvement node was added to carry it, evidenced from the original DFN-1 description and the case report's spasticity findings, and the orphan phenotypes (ataxia, the psychiatric features) were wired into the neurodegeneration node. The bundled Neuronal Mitochondrial Dysfunction node was split, per the single-scale discipline, into Mitochondrial Morphology and Dynamics Disturbance and Neuronal Bioenergetic Failure. The split exposed a three-way direction conflict that the bundle had hidden: fibroblasts and knockdown HeLa elongate, patient iPSC neurons fragment, and mouse hippocampal mitochondria shrink with upregulated Mtfp1. The node is scoped to dysregulated dynamics and says so, and the mouse link's limitations warn against reading the murine direction as the human one. The mouse link became RECAPITULATES against the morphology node instead of PARTIALLY_RECAPITULATES against the bundle. Terms: the psychiatric phenotype was split from the enum-root HP:0000708 Atypical behavior into HP:0000751 Personality changes and HP:0011999 Paranoia, both of which exist and both of which the GeneReviews sentence names. CL:1001474 medium spiny neuron was removed as an unsupported specificity leap, since the neuropathology resolves only to basal ganglia and striatum. GO:0045041 was dropped from the escort node as the wrong direction (import INTO the IMS is upstream of what this complex does; GO:0045039 is retained). Also added: prevalence (CASES_IN_LITERATURE / ULTRA_RARE, with a note that no numeric rate is asserted because the case counts are not in a cached abstract), a four-phase progression block, onset categories, a REFUTE item and prose softening for penetrance from PMID:40597358 (a hemizygous adolescent with dystonia and no hearing loss), the basal ganglia iron phenotype from the same case, primary deletion-architecture evidence from PMID:36056138, vestibular-sparing evidence, and a preclinical-only vitamin E entry marked as a cell-culture lead rather than a therapy. The FAILS_TO_RECAPITULATE link's evidence was flipped from REFUTE to SUPPORT: the quote establishes the failure the link asserts, so it supports the link while contradicting the import account. Validation run and read to completion:

Claude Code ▸
Deafness-Dystonia-Optic Neuronopathy Syndrome (Mohr-Tranebjaerg Syndrome): Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 24 citations 2026-09-04T21:23:31.168647

Deafness-Dystonia-Optic Neuronopathy Syndrome (Mohr-Tranebjaerg Syndrome): Comprehensive Research Report

1. Disease Information

Overview. Deafness-Dystonia-Optic Neuronopathy (DDON) syndrome — universally known in the clinical literature as Mohr-Tranebjaerg syndrome (MTS) — is a rare X-linked recessive mitochondrial protein-import disorder caused by loss-of-function variants in TIMM8A (translocase of inner mitochondrial membrane 8A, historically called DDP1, "deafness-dystonia peptide 1"). It is a progressive, multisystem neurodegenerative condition: affected males develop prelingual/early-childhood sensorineural hearing loss of the auditory-neuropathy type, followed in the second decade by progressive dystonia and/or ataxia, then in the third decade by optic atrophy and progressive visual loss, and by the fourth to fifth decade by cognitive decline (dementia) with psychiatric features (GeneReviews, Tranebjaerg et al., updated 2019; NBK1216) [https://www.ncbi.nlm.nih.gov/books/NBK1216/].

Key identifiers: - OMIM: #304700 (Mohr-Tranebjaerg syndrome; MTS) — phenotype; gene locus TIMM8A OMIM 300356 - Orphanet: ORPHA:52368 [https://www.orpha.net/en/disease/detail/52368] - MONDO: MONDO:0010578 - Gene: HGNC:11817 (TIMM8A); Xq22.1 - MedGen: C0796074 ("Deafness dystonia syndrome") [https://www.ncbi.nlm.nih.gov/medgen/162903] - GeneReviews*: NBK1216 [https://www.ncbi.nlm.nih.gov/books/NBK1216/] - ICD-10/11: no dedicated code; typically coded under H90.- (sensorineural hearing loss) + G24.- (dystonia) + H47.2- (optic atrophy) or as an "other specified" syndromic entry; MeSH lacks a distinct heading (indexed under "Deafness" and "Dystonic Disorders" cross-references).

Synonyms: Mohr-Tranebjaerg syndrome; MTS; Deafness-Dystonia syndrome; Deafness-dystonia-optic atrophy syndrome; DFN-1 (deafness, X-linked 1, an older locus designation); Jensen syndrome (an older eponym for an overlapping/allelic phenotype now considered part of the MTS spectrum).

Evidence basis. The knowledge base for this disorder is aggregated-cohort/literature-derived rather than large-registry EHR data: it rests on case reports and small case series compiled into systematic reviews. A widely cited synthesis identified 91 affected individuals from 37 families worldwide (cited in GeneReviews, NBK1216), while a 2019 Chinese cohort paper noted only 69 MTS cases reported worldwide since the disorder's initial clinical description in 1960 (Wang et al. 2019, PMID:30634948) — the discrepancy reflects differing inclusion criteria and ongoing case accrual; there is no population-based registry.

2. Etiology

Disease Causal Factors

MTS is caused exclusively by loss-of-function pathogenic variants in TIMM8A — there is no known environmental, infectious, or multifactorial etiology. Two mutational classes account for essentially all cases (GeneReviews NBK1216): 1. Intragenic TIMM8A variants (point mutations, small insertions/deletions) causing hemizygous loss of function in males (or heterozygous carriage in females) — accounting for roughly half of molecularly solved cases (~22/42 in one reported cohort). 2. Contiguous gene deletions at Xq22.1 removing TIMM8A together with neighboring genes — most importantly BTK (Bruton tyrosine kinase), and sometimes TAF7L and DRP2 — producing a combined phenotype of MTS plus X-linked agammaglobulinemia (XLA) (~20/42 cases in the same cohort). Approximately 3–5% of individuals with a BTK pathogenic variant carry a large deletion extending through TIMM8A (GeneReviews NBK1453, X-Linked Agammaglobulinemia) [https://www.ncbi.nlm.nih.gov/books/NBK1453/]. Deletion sizes reported range from ~63 kb (BTK-only) to 149.7–196 kb (BTK + TIMM8A + TAF7L + DRP2) (Järvinen et al./Väliaho et al., J Hum Genet 2011) [https://www.nature.com/articles/jhg201161]; break points frequently fall within Alu and endogenous retroviral repeat elements. A 2022 mate-pair sequencing study mapped deletion break points in four additional MTS patients, refining the deletion architecture (Rendtorff et al., Sci Rep 2022, PMC9440042) [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440042/].

Risk Factors

  • Genetic risk factors: Male sex is itself the dominant "risk factor" because of X-linked recessive transmission — males with a maternal TIMM8A variant are essentially fully penetrant for the classic phenotype. A maternal history of a hemizygous or de novo germline/somatic mosaic TIMM8A variant is the operative genetic risk factor for offspring. No modifier genes or susceptibility loci beyond TIMM8A itself have been identified; the gene has only two exons and a nearby non-functional pseudogene (TIMM8AP1) that does not interfere with molecular testing (GeneReviews NBK1216).
  • Environmental risk factors: None established — this is a purely monogenic disorder. Age (progressive, cumulative organ damage) and family history (X-linked pedigree) are the only recognized "risk" correlates, not sex/lifestyle/occupational exposures.
  • Gene-environment interactions: None documented in the literature; no CTD or PheGenI records of environmental modifiers were located.

Protective Factors

  • No protective genetic variants or environmental/dietary protective factors have been reported. Skewed X-chromosome inactivation is invoked to explain why most heterozygous female carriers are mildly or asymptomatically affected (GeneReviews NBK1216), functioning as a natural "protective" mechanism in carrier females rather than a discrete allele.

3. Phenotypes

The clinical course follows a stereotyped four-stage sequence, though onset ages and severities vary considerably between and even within families (GeneReviews NBK1216; Frontiers case report, Chen et al. 2023, PMID:37325222) [https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1161940/full].

Phenotype Type Typical onset Progression Frequency Suggested HP term
Sensorineural/auditory-neuropathy hearing loss Symptom/lab (audiometric/ABR) ~18 months (range: congenital–postlingual) Rapidly progressive to profound before age 10; then stable Essentially 100% of hemizygous males (defining feature) HP:0000365 (Hearing impairment); more specifically HP:0008527 (Congenital sensorineural hearing impairment) or auditory neuropathy phenotype
Auditory neuropathy spectrum pattern (preserved OAE, absent/abnormal ABR, absent stapedial reflex) Laboratory/electrophysiologic Same as above Stable pattern once established Consistent finding across reported cases HP:0000407 (Sensorineural hearing impairment) with electrophysiologic auditory-neuropathy pattern
Dystonia Sign Teens (variable — some individuals unaffected into their 30s) Slowly progressive; gait instability → cane → wheelchair; contractures Majority of adult males; highly variable rate HP:0001332 (Dystonia)
Ataxia Sign Overlapping with dystonia onset Progressive Present in a subset (dystonia/ataxia overlap) HP:0001251 (Ataxia)
Optic atrophy / progressive visual loss Sign/symptom ~age 20 Photophobia → reduced acuity → central scotomas → legal blindness by 30–40y Majority of surviving affected males HP:0000648 (Optic atrophy); HP:0000572 (Visual loss)
Cognitive decline/dementia Symptom ~age 40 Progressive Common in those surviving to middle age HP:0000726 (Dementia)
Psychiatric/behavioral disturbance (personality change, paranoia, aggression, self-mutilation) Behavioral Childhood onward, worsening with age Progressive Frequently reported; may mimic autism-spectrum features HP:0000708 (Behavioral abnormality); HP:0000751 (Personality changes/agitation)
Dysphagia with aspiration risk Symptom (late) Late disease Progressive Late complication HP:0002015 (Dysphagia); HP:0006532 (Recurrent aspiration pneumonia)
Peripheral sensory neuropathy Sign Adulthood Mild, slowly progressive Subset HP:0007141 (Sensory neuropathy)
Frequent hip fractures Complication Adulthood Related to poor coordination Reported feature HP:0002827 (Hip dysplasia) not exact — better: HP:0002996 (Fracture) related to falls
Female-carrier phenotype: mild hearing loss and/or focal dystonia (e.g., writer's cramp) Sign Later-onset, milder Variable/stable Minority of carriers, more common in older carriers HP:0000365; HP:0001332 (milder, later, focal)

Notably absent features (useful for differential diagnosis): seizures are not characteristic; cardiomyopathy does not occur; respiratory function is normal except for aspiration-related compromise; fertility in affected males is normal (GeneReviews NBK1216).

Quality of life impact: Combined progressive deaf-blindness plus a movement disorder produces severe, compounding functional impairment; GeneReviews explicitly recommends referral to state Deafblind Projects and tactile sign-language training once vision loss compounds the pre-existing deafness — a functional profile comparable to acquired Usher-type deafblindness but with a superimposed motor disorder. No disease-specific EQ-5D/SF-36 data were located in the literature search.

4. Genetic/Molecular Information

Causal gene: TIMM8A (translocase of inner mitochondrial membrane 8 homolog A, yeast), HGNC:11817, located at Xq22.1, OMIM 300356. The gene is remarkably compact — only two exons, encoding a 97-amino-acid* intermembrane-space protein (GeneReviews NBK1216).

Discovery: The gene (originally named DDP, "deafness-dystonia peptide") was first identified by positional cloning in 1996: "A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness" (Jin H et al., Nat Genet. 1996;14(2):177-80, PMID:8841189) [https://www.nature.com/articles/ng1096-177].

Variant classes: - Missense (e.g., the classic C66W mutation altering the conserved "twin CX₃C" motif — see mechanism below) - Frameshift/small indel (e.g., c.232_233insCAAT → p.Leu78Serfs21; c.133_135delGAG → p.Glu45del; Wang et al. 2019, PMID:30634948) - Initiation-codon loss (c.1A>T, p.Met1Leu — abolishes protein production entirely; Neighbors et al., Mol Genet Genomic Med. 2020, PMID:31903733) [https://onlinelibrary.wiley.com/doi/full/10.1002/mgg3.1121] - Contiguous gene deletions at Xq22.1 spanning TIMM8A, BTK, TAF7L, and/or DRP2 (Väliaho et al., J Hum Genet.* 2011) [https://www.nature.com/articles/jhg201161]; whole-gene deletions detected only by chromosomal microarray or copy-number analysis (e.g., Xq22.1(100,593,213-100,609,547)×0; Wang et al. 2019).

Variant classification (ACMG/ClinVar): Nearly all reported TIMM8A variants are classified pathogenic/likely pathogenic given the tight genotype-phenotype correlation and functional loss-of-function data; no benign missense variants with clinical significance are reported. De novo occurrence is frequent, and germline mosaicism has been invoked (though not molecularly proven in published pedigrees) to explain simplex cases with unaffected/untested mothers (GeneReviews NBK1216).

Population frequency: Given extreme rarity, TIMM8A pathogenic alleles are essentially absent from population reference databases (gnomAD); no meaningful population allele frequency or carrier-frequency estimate exists in the literature.

Somatic vs. germline: Exclusively germline; no somatic/mosaic tumor association reported (unrelated to TIMM8A's reported role as an immune-infiltration/PD-L1-correlated marker in some cancer bioinformatics studies, which is not a disease-causing association).

Functional consequence — loss of function via disrupted intermembrane-space chaperone assembly: - TIMM8a/DDP1 functions with its obligate partner TIMM13 as a small-TIM chaperone complex in the mitochondrial intermembrane space, escorting hydrophobic precursor proteins (notably components destined for the TIM23 inner-membrane translocase) across the aqueous intermembrane space to prevent aggregation (Koehler CM et al., Hum Mol Genet. 2002, PMID:11875042 — "Human deafness dystonia syndrome is caused by a defect in assembly of the DDP1/TIMM8a-TIMM13 complex") [https://pubmed.ncbi.nlm.nih.gov/11875042/]. TIMM8a assembles into a ~70 kDa hetero-hexameric complex with TIMM13 via a conserved "twin CX₃C" zinc-binding motif. - The classic pathogenic missense C66W disrupts Zn²⁺ coordination by the Cys₄ motif, destabilizing the protein so it cannot assemble the DDP1·TIM13 complex (Roesch K et al., PMID:11956200 — "The C66W mutation in the deafness dystonia peptide 1 (DDP1) affects the formation of functional DDP1.TIM13 complexes"). - The DDP1·hTim13 complex directly contacts translocation intermediates of human Tim23 and is required for its import into the inner membrane (Hofmann S et al., PMID:11489896 — "Role of the deafness dystonia peptide 1 (DDP1) in import of human Tim23"); loss of this chaperone activity therefore secondarily impairs assembly of the entire TIM23 presequence translocase, and downstream import of a broad range of inner-membrane and matrix proteins. - MTS was among the first disorders explicitly framed as "a mitochondrial disease" caused by defective protein import machinery rather than by an oxidative-phosphorylation subunit defect per se (Koehler CM et al., PNAS 1999, PMID:10051608 — "Human deafness dystonia syndrome is a mitochondrial disease"). - A neuron-specific downstream consequence has been elucidated recently: hTim8a is required for Complex IV (cytochrome c oxidase) assembly specifically in neuronal cells, providing a mechanistic bridge between a ubiquitously expressed import chaperone and the neuron-selective clinical phenotype (Kang Y et al., PMC6861005) [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861005/]. - DDP1/TIMM8a also interacts with the endosomal signal-transduction adaptor STAM1, suggesting a possible non-canonical trafficking role beyond core mitochondrial import (Wilkinson SJ et al., J Biol Chem. 2003, PMID:12745081). - A recently identified rescue pathway: overexpression of CHCHD2, another intermembrane-space small protein, rescues mitochondrial dysfunction and restores neurite outgrowth in patient iPSC-derived neurons, positioning CHCHD2 as a downstream effector/compensatory node in MTS pathogenesis (Liu et al., Cell Death Dis. 2025, PMID:40075073) [https://pmc.ncbi.nlm.nih.gov/articles/PMC11903874/].

Modifier genes: None formally established; phenotypic variability in carrier females is attributed to skewed X-inactivation rather than a discrete modifier locus.

Epigenetic information: No disease-specific DNA methylation or chromatin studies were located; X-inactivation skewing (an epigenetic phenomenon) is the principal epigenetic mechanism invoked for carrier-female variability.

Chromosomal abnormalities: Contiguous Xq22.1 microdeletions (see above) are the principal structural-variant class; detectable by chromosomal microarray (CMA) but potentially missed by exome/panel sequence-only analysis, which is why GeneReviews recommends CMA as an appropriate first-tier test when XLA co-occurs.

5. Environmental Information

  • Environmental factors: None identified as causal or modifying; this is a fully penetrant monogenic mitochondrial-import disorder with no reported toxin, radiation, or pollutant association in CTD/PubMed searches.
  • Lifestyle factors: Not applicable to disease causation; general supportive lifestyle measures (nutrition for dysphagia, physical activity within motor limits) are part of symptomatic management rather than etiologic modifiers.
  • Infectious agents: None. (Note: the co-occurring XLA phenotype in contiguous-deletion cases confers susceptibility to recurrent bacterial infections due to B-cell deficiency — this is a consequence of the linked BTK deletion, not an infectious cause of MTS itself.)

6. Mechanism / Pathophysiology

Causal chain (ordered, from molecular lesion to clinical manifestation)

  1. A loss-of-function TIMM8A variant (point mutation, frameshift, or contiguous Xq22.1 deletion) leads to absent or non-functional TIMM8a (DDP1) protein, or a protein unable to bind Zn²⁺ via its twin CX₃C motif (demonstrated directly for C66W; PMID:11956200) [DIRECT — biochemically demonstrated].
  2. Loss of functional TIMM8a leads to failure of TIMM8a–TIMM13 hetero-hexameric complex assembly in the mitochondrial intermembrane space (Koehler et al., PMID:11875042) [DIRECT].
  3. Failure of the TIMM8a·TIMM13 chaperone complex results in impaired escort/import of hydrophobic precursor proteins across the intermembrane space, most critically components of the TIM23 presequence translocase (Hofmann et al., PMID:11489896) [DIRECT — shown for human Tim23 import in vitro/in organello].
  4. Defective TIM23 translocase assembly leads to broader dysfunction of inner-membrane and matrix protein import generally, and — in a neuron-specific manner — impaired assembly of respiratory Complex IV (cytochrome c oxidase) (Kang et al., PMC6861005) [PARTLY INFERRED for the general-import step; DIRECT for the neuronal Complex IV finding, shown in a neuronal cell model].
  5. Mitochondrial import/respiratory dysfunction leads to a bioenergetic and mitochondrial-dynamics deficit in metabolically demanding, post-mitotic cells: patient fibroblasts show abnormal mitochondrial elongation/fusion (Neighbors et al., PMID:31903733), and a mouse model shows reduced mitochondrial size in hippocampal neurons correlating with upregulation of the fission factor MTFP1/MTP18 (Zhao et al., Front Cell Neurosci. 2022, PMID:32820032; PMC9453755) [DIRECT, model-organism evidence].
  6. Chronic mitochondrial dysfunction in the most vulnerable, high-energy-demand neuronal populations leads to selective neuronal cell death, producing the tissue-specific lesions documented on human temporal-bone and neuropathologic study: near-total loss of cochlear spiral ganglion neurons and severe loss of vestibular (Scarpa's) ganglion neurons (auditory neuropathy), retinal ganglion cell and optic nerve degeneration, striatal and cortical involvement (dystonia, hypometabolism on PET over the right striatum and parietal cortex), and marked occipital-lobe/visual-cortex atrophy with neuronal loss (Merchant et al./Ujike et al., PMID:11803487 — "Neuronal cell death in the visual cortex is a prominent feature of the X-linked recessive mitochondrial deafness-dystonia syndrome") [DIRECT, human neuropathology].
  7. Progressive loss of these discrete, spatially separated neuronal populations leads to the clinical tetrad in temporal sequence: (a) early spiral/vestibular ganglion loss → prelingual/childhood sensorineural hearing loss with an auditory-neuropathy electrophysiologic signature (preserved otoacoustic emissions, absent/abnormal ABR, absent stapedial reflex — reflecting a neural, not cochlear-hair-cell, lesion); (b) basal ganglia/cortical involvement → adolescent-onset dystonia/ataxia; (c) retinal ganglion cell/optic nerve/visual cortex loss → young-adult optic atrophy and progressive visual loss; (d) diffuse cortical and subcortical neurodegeneration with generalized brain atrophy → mid-adult dementia and psychiatric disturbance, and late dysphagia from bulbar/brainstem involvement with aspiration pneumonia risk.
  8. In carrier females, the same molecular lesion is present but its phenotypic expression is buffered by skewed X-chromosome inactivation, so that only a minority (typically older carriers) manifest mild hearing loss and/or focal dystonia — an inferred rather than fully mechanistically demonstrated modifier step.

Molecular pathways

  • Mitochondrial protein import machinery: TIM8/TIM13 small-TIM chaperone complex → TIM23 presequence translocase (KEGG/Reactome: mitochondrial protein import pathway). GO: GO:0045039 (protein insertion into mitochondrial inner membrane), GO:0045041 (protein import into mitochondrial intermembrane space), GO:1990542 (mitochondrial transmembrane transport).
  • Downstream: oxidative phosphorylation / Complex IV assembly (GO:0033617, mitochondrial respiratory chain complex IV assembly).
  • Mitochondrial dynamics/fission: MTFP1 (MTP18)-mediated fission pathway, implicated in the mouse hippocampal phenotype (PMID:32820032).

Cellular processes

  • Impaired mitochondrial protein import and downstream bioenergetic failure, altered mitochondrial morphology/dynamics (elongation/fusion in fibroblasts; reduced size via increased fission signaling in neurons), and ultimately neuronal cell death (a form of chronic, degeneration-associated cell loss rather than classical developmental apoptosis) in vulnerable post-mitotic neuronal populations. GO: GO:0007005 (mitochondrion organization), GO:0006915 (apoptotic process, as the terminal event in ganglion-cell/retinal-ganglion-cell loss).

Protein dysfunction

  • Loss-of-function of a 97-aa, twin-CX₃C zinc-finger intermembrane-space chaperone; the C66W variant is the structurally best-characterized example, abolishing Zn²⁺ coordination and complex assembly (PMID:11956200). UniProt: O60220 (TIMM8A_HUMAN).

Metabolic changes

  • Secondary respiratory-chain (Complex IV) impairment reported in at least one muscle biopsy case (mild Complex IV deficiency, no mtDNA abnormality; GeneReviews NBK1216), consistent with an oxidative-phosphorylation assembly defect downstream of the import block, though muscle mitochondrial enzymology is usually otherwise normal — the defect is neuron-selective rather than systemic.

Immune system involvement

  • Not part of the core MTS mechanism; immune dysfunction (agammaglobulinemia, B-cell deficiency) occurs only in the contiguous-deletion subtype as a direct consequence of concomitant BTK loss, a distinct and independently characterized pathway (BTK signaling in B-cell receptor maturation), not an autoimmune or inflammatory feature of TIMM8a loss itself.

Tissue damage mechanisms

  • Chronic mitochondrial-import/bioenergetic insufficiency in high-energy-demand neurons → selective, progressive neurodegeneration (not acute ischemia, fibrosis, or necrosis) — histopathologically manifest as gliosis, microcalcification, and neuronal dropout in cochlear/vestibular ganglia, retina/optic nerve, visual cortex, striatum, and spinal cord dorsal columns.

Molecular/advanced profiling

  • iPSC-derived neuronal models from MTS patients show mitochondrial dysfunction correctable by CHCHD2 overexpression (PMID:40075073) — the most direct human-cell-based mechanistic model to date.
  • No large-scale transcriptomic/proteomic/metabolomic datasets specific to MTS patient tissue were identified in GEO/PRIDE/MetaboLights during this search; molecular characterization has relied on targeted biochemical and cell-biology assays (import assays, complex-assembly co-IP, fibroblast mitochondrial morphology) rather than omics screens.

Suggested GO terms: GO:0045039, GO:0045041, GO:1990542, GO:0033617, GO:0007005, GO:0006915. Suggested CL terms: spiral ganglion neuron (cochlear afferent neuron), vestibular (Scarpa's) ganglion neuron, retinal ganglion cell (CL:0000740), medium spiny neuron of striatum.

7. Anatomical Structures Affected

Organ level: - Primary: inner ear (cochlea and vestibular apparatus), optic nerve/retina, basal ganglia and cerebral cortex, spinal cord. - Secondary: bulbar/pharyngeal musculature (dysphagia → aspiration pneumonia, secondary pulmonary involvement); skeletal system (fracture risk from impaired coordination); in the contiguous-deletion subtype, the B-lymphocyte lineage/humoral immune system (agammaglobulinemia). - Body systems: nervous system (primary), sensory systems (auditory, visual), and — deletion subtype only — immune system.

Tissue/cell level: - Cochlear spiral ganglion neurons (auditory afferents) — near-total loss on temporal bone histopathology. - Vestibular (Scarpa's) ganglion neurons — severe loss, though clinically silent (vestibular function testing typically normal despite histologic loss). - Retinal ganglion cells and their axons forming the optic nerve. - Visual cortex (calcarine cortex/occipital lobe) neurons — marked atrophy and cell loss (PMID:11803487). - Striatal neurons — implicated in the dystonia phenotype via PET hypometabolism. - Spinal cord dorsal root ganglia/posterior columns — atrophy with sensory fiber loss.

Suggested UBERON terms: UBERON:0001846 (spiral ganglion), UBERON:0009713 (vestibular ganglion), UBERON:0000966 (retina), UBERON:0000941 (optic nerve), UBERON:0002250 (or striatum-specific term), UBERON:0002436 (primary visual cortex), UBERON:0002240 (spinal cord).

Subcellular level: - Mitochondrial intermembrane space (site of TIMM8a·TIMM13 complex; GO Cellular Component GO:0005758, mitochondrial intermembrane space) and mitochondrial inner membrane (GO:0005743) — the primary subcellular lesion site; secondary abnormalities in mitochondrial morphology/dynamics affect the entire organelle.

Localization: Bilateral and symmetric involvement throughout — bilateral sensorineural hearing loss, bilateral optic atrophy, generalized (non-lateralized) dystonia/ataxia and cortical/subcortical atrophy.

8. Temporal Development

Onset: Congenital-to-early-childhood for hearing loss (mean ~18 months; range congenital to postlingual); progressively later ages of onset for each subsequent system (teens for dystonia/ataxia; ~20 years for visual decline; ~40 years for dementia) — an unusually well-defined, layered temporal cascade for a single-gene disorder (GeneReviews NBK1216).

Progression: - Stages (informally staged by system involvement rather than a formal numeric staging system): (1) isolated auditory-neuropathy deafness (childhood); (2) deafness + emerging dystonia/ataxia (adolescence); (3) deafness + dystonia + optic atrophy (young adulthood); (4) deafness + dystonia + blindness + dementia/psychiatric disease (midlife). - Rate: Hearing loss progresses rapidly (to profound, typically before age 10) and then plateaus; neurologic, visual, and neuropsychiatric involvement are markedly more variable in rate, ranging from a benign, minimally symptomatic course into the 30s in some individuals to rapid, severely disabling progression in others. - Course pattern: Chronic, progressive, non-relapsing-remitting (unlike many autoimmune/inflammatory neurologic diseases) — a steady neurodegenerative decline. - Duration: Lifelong/chronic; not self-limited.

Patterns: - No spontaneous or treatment-induced remission has been reported for any component of the phenotype. - Critical periods: Early identification of the auditory-neuropathy hearing-loss pattern (via ABR/OAE testing) represents a critical window for early habilitation (sign language, early intervention services) before the compounding effects of later dystonia and vision loss; GeneReviews frames early multidisciplinary intervention as substantially improving functional trajectory even though it does not alter the underlying neurodegeneration.

9. Inheritance and Population

Epidemiology: Prevalence and incidence are formally unknown — MTS is classified as an ultra-rare disease. The most comprehensive literature aggregation reports 91 affected individuals in 37 families worldwide (GeneReviews NBK1216); an independent 2019 cohort study states only 69 MTS cases reported globally since 1960 (Wang et al. 2019, PMID:30634948) — both figures indicate a disease so rare that formal per-100,000 prevalence/incidence rates cannot be calculated. As a comparative benchmark cited in GeneReviews: all-cause dystonia prevalence is 70–329 per million, and hearing impairment overall is ~1:800, with only ~1% X-linked — underscoring how numerically small the MTS subset is within either broader category.

Inheritance pattern: X-linked recessive. Affected individuals are almost exclusively male (hemizygous); heterozygous females are typically unaffected or mildly affected.

Penetrance: Essentially complete for the classic phenotype in hemizygous males; age-dependent penetrance is a defining feature — features accrue with age rather than all being present from birth, so "penetrance" for any single late feature (e.g., dementia) should be assessed relative to survival to the age at which that feature typically appears.

Expressivity: Highly variable, both between families (interfamilial) and within a single family (intrafamilial) sharing an identical variant — timing and severity of dystonia, visual loss, and cognitive/psychiatric decline are not reliably predictable even from genotype (GeneReviews NBK1216).

Genetic anticipation: Not reported; MTS is not a repeat-expansion disorder.

Germline mosaicism: Suspected as an explanation for simplex male cases with an untestable/negative maternal result, but not molecularly proven in the literature to date.

Founder effects: Not formally documented; most families carry private (family-specific) variants, consistent with recurrent de novo mutation rather than a single ancestral founder allele, though the disease has been described across diverse populations (European, Chinese — Wang et al. 2019 — Spanish — Vera et al., PMID:18952432, and others), arguing against a single founder.

Consanguinity: Not a relevant factor for an X-linked recessive disorder transmitted from carrier mothers (as opposed to autosomal recessive disorders, where consanguinity elevates risk); no specific consanguinity association reported.

Carrier frequency: Not established in population databases given extreme rarity.

Population demographics: - No specific ethnic/geographic enrichment identified; cases reported from Europe, North America, and Asia (including the first reported Chinese cohort, Wang et al. 2019). - Sex ratio: Overwhelmingly male-affected, consistent with X-linked recessive transmission; carrier females are the near-exclusive female "affected" category, typically with milder, later-onset disease. - Age distribution: Spans from infancy (hearing-loss onset) through late adulthood (surviving affected males with dementia); reported lifespan is highly variable — GeneReviews cites a documented range from death at age 16 (rapid dystonia progression) to survival into the sixties within the same family, illustrating that MTS is not uniformly life-limiting in early life but can be.

Recurrence risk (genetic counseling): - Carrier mother × unaffected father: 50% of sons affected; 50% of daughters carriers (usually unaffected/mildly affected). - Affected/carrier father: transmits the variant to 100% of daughters (carriers, usually unaffected/mildly affected) and 0% of sons. - Simplex cases with maternal testing negative: residual sibling recurrence risk above general population background due to possible germline mosaicism. - A 2023 case report explicitly frames MTS as "an insidious disorder with high recurrence risk," emphasizing the importance of hearing loss as a sentinel early sign prompting genetic counseling before neurologic/visual/cognitive decline manifests (Chen et al., Front Neurol. 2023, PMID:37325222).

10. Diagnostics

Clinical suspicion triggers (GeneReviews NBK1216): a male with early-onset auditory-neuropathy-pattern sensorineural hearing loss (preserved otoacoustic emissions + absent/abnormal auditory brainstem response + absent stapedial reflex, with a structurally normal inner ear on CT/MRI), especially when accompanied by a progressive movement disorder, visual decline, or a suggestive X-linked family history.

Laboratory/electrophysiologic tests: - Audiometry, otoacoustic emissions (OAE), auditory brainstem response (ABR), stapedial reflex testing — collectively establish the auditory neuropathy signature. - Electroretinogram (ERG) — typically normal, distinguishing the optic neuronopathy of MTS from retinal dystrophies (e.g., Usher syndrome). - Visual field testing, color vision testing — central scotomas and acquired dyschromatopsia in later disease.

Imaging: - Temporal bone/inner-ear CT or MRI — normal anatomy (rules out structural causes of deafness). - MRI reveals small/hypoplastic cochlear nerves in some cases (Wang et al. 2019, PMID:30634948). - Brain MRI/PET — generalized cerebral and marked occipital-lobe atrophy from age ~40 (or earlier); PET shows hypometabolism over the right striatum and parietal cortex; a 2025 case report additionally documented basal ganglia iron deposition on MRI in a novel-mutation case (PMC12211147) [https://pmc.ncbi.nlm.nih.gov/articles/PMC12211147/].

Genetic testing (primary diagnostic modality): - Sequence analysis of TIMM8A — detects point mutations/small indels (roughly half of solved cases). - Gene-targeted deletion/duplication analysis or chromosomal microarray (CMA) — required to detect the ~50% of cases due to larger deletions, especially contiguous BTK-TIMM8A deletions; CMA is specifically recommended when co-occurring immunodeficiency (XLA) is suspected. - Multigene deafness/auditory-neuropathy panels including TIMM8A — appropriate first-tier approach for isolated pediatric auditory-neuropathy presentations (as used diagnostically in Wang et al. 2019, identifying MTS 1.8% of the time (3/168 cases) in a targeted auditory-neuropathy sequencing cohort — the only quantitative diagnostic-yield figure identified in this search). - Whole-exome/genome sequencing — appropriate when panel testing is uninformative or the phenotype is atypical (e.g., the 2025 case with basal ganglia iron deposition but no hearing loss, PMC12211147, illustrating expanding phenotypic recognition via broader sequencing).

Clinical/diagnostic criteria: No formal consensus diagnostic-criteria statement (e.g., no DSM/dedicated society criteria) exists; diagnosis rests on the clinical tetrad plus confirmatory TIMM8A molecular testing.

Differential diagnosis (GeneReviews NBK1216, with distinguishing features): | Disorder | Distinguishing feature vs. MTS | |---|---| | MELAS (mitochondrial) | Short stature, seizures typical; dystonia uncommon | | Usher syndrome | Retinal dystrophy (not optic atrophy); abnormal ERG | | Wolfram syndrome (WFS1) | Juvenile diabetes mellitus; no dystonia | | Friedreich ataxia | Cardiomyopathy common; depressed (not brisk) reflexes; hearing loss atypical | | McLeod syndrome (XK) | Acanthocytosis, cardiomyopathy | | Arts syndrome (PRPS1) | Hearing loss without dystonia predominates | | MEGDEL syndrome (SERAC1) | Leigh-like MRI features, 3-methylglutaconic aciduria | | SUCLA2-related mtDNA depletion | Normal ophthalmologic exam; abnormal muscle histology, methylmalonic aciduria |

Screening: No population newborn-screening or carrier-screening program exists given extreme rarity; family-specific molecular testing (carrier testing, prenatal diagnosis, preimplantation genetic testing) is offered once a familial variant is identified (GeneReviews NBK1216).

11. Outcome/Prognosis

Survival/mortality: No formal survival curves or 5-/10-year survival statistics exist given the disease's rarity; documented lifespan is highly variable even within a single family, with reported deaths as early as age 16 (rapid dystonia progression) and survival into the sixties in other affected relatives (GeneReviews NBK1216). Aspiration pneumonia secondary to late-stage dysphagia is a recognized cause of morbidity/mortality risk.

Morbidity/function: Progressive combined deaf-blindness plus a movement disorder produces severe cumulative disability; most affected males eventually require mobility aids (cane → wheelchair) and augmentative/tactile communication support. No disease-specific validated quality-of-life instrument scores were located.

Disease course/complications: Aspiration pneumonia (from dysphagia), fracture risk (from impaired coordination/falls), and — in the contiguous-deletion subtype — recurrent bacterial infections from concomitant agammaglobulinemia (requiring immunoglobulin replacement, per standard XLA management).

Recovery potential: None — this is a progressive neurodegenerative disorder with no disease-modifying therapy; management is exclusively supportive/rehabilitative (see Treatment).

Prognostic factors: No validated biomarkers or clinical scores predict individual rate of progression; genotype (deletion vs. point mutation) does not clearly predict severity except for the presence/absence of concurrent XLA in deletion cases (GeneReviews NBK1216).

12. Treatment

There is no disease-modifying or curative therapy; management is entirely symptomatic/supportive and multidisciplinary (GeneReviews NBK1216).

Hearing loss: - Early auditory habilitation, hearing aids (variable benefit given the neural, not cochlear, basis of the deficit), sign-language/tactile-sign instruction, and early-intervention/school-based services. - Cochlear implantation has been attempted but shows limited/variable effectiveness because the lesion is neuronal (spiral ganglion loss) rather than cochlear hair-cell loss — a mechanistic mismatch analogous to other auditory-neuropathy-spectrum disorders. One reported pediatric case with DDON showed only "fair" cochlear-implant performance with speech-language skills markedly below age norms (Brookes et al. 2008, cited via secondary literature); broader auditory-neuropathy cochlear-implant outcome data (PMC10679445) suggest outcomes are generally more variable than in classic sensorineural (hair-cell) deafness. Suggested NCIT terms: NCIT:C15329 (Surgical Procedure) for the implantation action, with the device itself captured via a qualifiers predicate-value pair to NCIT:C157820 (Cochlear Implant) per the medical-device-vs-clinical-action convention.

Vision: Corrective lenses/low-vision aids; community vision services; referral to deaf-blind service programs once visual loss compounds pre-existing deafness.

Dystonia/movement disorder: - Physical medicine and rehabilitation; physical therapy (mobility, contracture prevention — NCIT:C15302, Physical Therapy); occupational therapy (adaptive devices for activities of daily living). - Pharmacologic: baclofen (CHEBI:2972), tizanidine, botulinum toxin injection, and anti-parkinsonian agents used as for other forms of dystonia — standard symptomatic pharmacotherapy (NCIT:C15986, Pharmacotherapy), not MTS-specific.

Psychiatric/behavioral: Standard psychotropic medications and behavioral therapy for OCD-, ADHD-, and autism-spectrum-like features; stress reduction strategies.

Feeding/dysphagia: Feeding therapy, thickened/modified diets, and — in severe cases — nasogastric or gastrostomy tube feeding (NCIT:C15447, Dietary Intervention, plus procedural feeding-support interventions).

Genetic counseling: NCIT:C15240, Genetic Counseling — a core management component given the high familial recurrence risk emphasized in the 2023 case report (PMID:37325222).

Contiguous-deletion (XLA-overlap) subtype: Standard XLA management — regular intravenous or subcutaneous immunoglobulin replacement and prompt treatment of bacterial infections — is added when BTK is co-deleted.

Experimental/investigational: No registered clinical trials for MTS-specific gene therapy, RNA-based therapy, or targeted small-molecule correction were identified via this search (a search of ClinicalTrials.gov and WHO ICTRP for "TIMM8A" or "Mohr-Tranebjaerg" returned no active MTS-specific interventional trials at the time of this report). The most advanced preclinical therapeutic lead is the CHCHD2 overexpression rescue demonstrated in patient-derived iPSC neurons (PMID:40075073), which is a cell-model proof-of-concept, not a clinical intervention.

Surveillance: Annual audiologic evaluation; regular speech-language evaluation; regular neurologic exam to monitor dystonia and medication titration; periodic physical/occupational therapy review; annual developmental/vision assessment in childhood; individualized psychiatric follow-up; ongoing assessment of family/caregiver support needs (GeneReviews NBK1216).

13. Prevention

  • Primary prevention: Not applicable in the traditional sense (no modifiable risk-factor exposure to avoid); the only "primary prevention" avenue is reproductive genetic counseling and prenatal or preimplantation genetic testing once a familial TIMM8A variant is identified, allowing informed reproductive decision-making (GeneReviews NBK1216).
  • Secondary prevention (early detection): Newborn hearing screening (universal in most developed health systems) is the practical entry point for early case detection, since prelingual auditory-neuropathy hearing loss is the earliest and most consistent manifestation; a positive/abnormal auditory-neuropathy pattern (preserved OAE with abnormal ABR) in a male infant should prompt consideration of genetic hearing-loss panel testing including TIMM8A.
  • Tertiary prevention: Early multidisciplinary intervention (audiology, ophthalmology, neurology, physical/occupational therapy, psychiatry) aims to prevent secondary complications — communication delay, contractures, malnutrition/aspiration from unrecognized dysphagia, and psychosocial morbidity — even though it cannot alter the underlying neurodegenerative trajectory.
  • Immunization: Not disease-specific, though in the contiguous BTK-deletion subtype, live-vaccine avoidance and standard XLA immunization precautions apply as they would for any agammaglobulinemic patient.
  • Screening: Carrier screening and prenatal/preimplantation genetic testing are offered on a family-specific basis once the pathogenic variant is known; there is no population-level MTS screening program given its rarity.
  • Behavioral interventions/public health: Not applicable — no behavioral or population-level environmental intervention modifies risk for this monogenic disorder.

14. Other Species / Natural Disease

  • Taxonomy: No naturally occurring MTS-equivalent disease has been reported in non-human species (companion animals, livestock, or wildlife); no OMIA entry for a spontaneous TIMM8A-associated veterinary phenotype was identified.
  • Orthologous gene: The murine ortholog is Timm8a1 (note the added "1" reflecting a mouse-specific paralog nomenclature; NCBI Gene, MGI). Comparative biology is discussed under Model Organisms below.
  • Comparative pathology/evolutionary conservation: The TIM8/TIM13 small-TIM chaperone system is evolutionarily conserved from yeast (Saccharomyces cerevisiae Tim8p/Tim13p) to humans; the human C66W disease mutation, when introduced into the homologous yeast residue, likewise destabilizes the yeast complex (Koehler et al., PMID:11875042), and the human DDP1·hTim13 complex can functionally complement the yeast TIM8·TIM13 complex — strong functional conservation across ~1 billion years of eukaryotic evolution, though yeast lack the specialized neuronal Complex IV dependency seen in humans.
  • Transmission/zoonotic potential: Not applicable — a purely genetic disorder with no infectious or zoonotic component.

15. Model Organisms

Genetic mouse model: A CRISPR/knock-in mouse carrying a homologous frameshift mutation, Timm8a1-I23fs49X, has been generated and characterized (Zhao Y et al., Front Cell Neurosci. 2022;16:972964, PMID:32820032 for the companion mechanistic paper) [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453755/].

Phenotype recapitulation: - Hearing impairment in both male and female mutant mice — recapitulates the human auditory phenotype. - Anxiety-like behavior (elevated plus maze) and cognitive deficit (Morris water maze) in mutant mice — recapitulates the human psychiatric/cognitive component. - Female mutant mice additionally showed motor coordination deficits (balance beam test) — a partial correlate of the human dystonia/ataxia phenotype. - Mechanistically, electron microscopy showed no overt neuronal loss in the hippocampus, but a significant reduction in mitochondrial size, correlating with upregulation of Mtfp1/Mtp18, a positive regulator of mitochondrial fission — offering a candidate proximate mechanism (altered mitochondrial dynamics) distinct from, or upstream of, the frank neuronal death documented in human neuropathology.

Model limitations: The mouse model captures hearing, anxiety/cognitive, and (in females) coordination phenotypes but — based on available reporting — does not reproduce the severe, progressive optic atrophy/blindness or the marked neuronal cell death documented in human temporal-bone and visual-cortex neuropathology (PMID:11803487); this represents a translational gap between rodent and human vulnerability of retinal ganglion cells/optic nerve, an area flagged as worth explicit HUMAN_MODEL_MISMATCH framing in mechanistic curation (the model shows a subcellular/mitochondrial-dynamics phenotype without the overt neurodegeneration central to the human disease).

Cellular/iPSC models: Patient-derived induced pluripotent stem cell (iPSC)-derived neurons have been generated and characterized for mitochondrial dysfunction, with CHCHD2 overexpression shown to rescue mitochondrial function and neurite outgrowth (PMID:40075073) — currently the most disease-relevant human cellular model, useful for mechanistic and candidate-therapeutic studies. Patient dermal fibroblasts have also been used directly to demonstrate loss of TIMM8a protein, reduced TIMM13 steady-state levels, and altered mitochondrial fusion/elongation morphology for specific variants (Neighbors et al., PMID:31903733).

Yeast model: The orthologous yeast Tim8p/Tim13p system has been used to model the biochemical consequence of the human C66W mutation, demonstrating loss of complex stability when the homologous cysteine is mutated (Koehler et al., PMID:11875042) — a well-established comparative-biology tool for dissecting the core import-chaperone mechanism, though yeast obviously cannot model the neurologic/sensory phenotype.

Research applications: These models collectively support study of (1) the biochemical/structural basis of TIMM8a–TIMM13 complex assembly (yeast, biochemical reconstitution); (2) cell-autonomous mitochondrial dysfunction and candidate rescue pathways (iPSC neurons, fibroblasts); and (3) systemic auditory, cognitive, and motor phenotypes plus mitochondrial-dynamics mechanism (Timm8a1 mutant mouse). No organoid, non-human-primate, or zebrafish MTS model was identified in this search.

Resource databases: MGI (mouse Timm8a1 allele records), Alliance of Genome Resources (cross-species TIMM8A orthology), Cellosaurus/ATCC (patient fibroblast/iPSC line deposits, where available).

Summary of Suggested Ontology Bindings for KB Curation

Category Suggested term(s)
Disease identifiers MONDO:0010578; OMIM:304700; ORPHA:52368; MedGen C0796074
Causal gene hgnc:11817 (TIMM8A)
Key phenotypes (HP) HP:0000365 (Hearing impairment) / HP:0008527 (Congenital sensorineural hearing impairment); HP:0001332 (Dystonia); HP:0001251 (Ataxia); HP:0000648 (Optic atrophy); HP:0000726 (Dementia); HP:0000708 (Behavioral abnormality); HP:0002015 (Dysphagia); HP:0006532 (Recurrent aspiration pneumonia)
Inheritance HP:0001417 (X-linked recessive inheritance)
GO biological processes GO:0045039, GO:0045041, GO:1990542, GO:0033617, GO:0007005
GO cellular component GO:0005758 (mitochondrial intermembrane space)
Cell types (CL) CL:0000740 (retinal ganglion cell); cochlear/spiral ganglion neuron and vestibular ganglion neuron (verify exact CL IDs via OAK before binding)
Anatomy (UBERON) UBERON:0001846 (spiral ganglion); UBERON:0009713 (vestibular ganglion); UBERON:0000966 (retina); UBERON:0000941 (optic nerve); UBERON:0002436 (primary visual cortex); UBERON:0002240 (spinal cord)
Treatments (NCIT) NCIT:C15302 (Physical Therapy); NCIT:C15329 (Surgical Procedure, cochlear implantation) + NCIT:C157820 (Cochlear Implant, device qualifier); NCIT:C15986 (Pharmacotherapy); NCIT:C15240 (Genetic Counseling); NCIT:C15447 (Dietary Intervention)
Chemicals (CHEBI) CHEBI:2972 (baclofen)

Note: all suggested ontology bindings above should be independently verified against OAK/current label text before insertion into a curated entry, per this repository's ontology-term validation contract; they are provided here as research leads, not pre-validated bindings.

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 22
Resolved 22
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 22
On topic 16
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 43
Resolved 40
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 3
Terms whose name was checked 16
Terms named correctly 10
Terms named as a different term 2
Terms whose name is worth a second look 4

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • UBERON:0001846 (2 mentions) - the report calls it "spiral ganglion"; UBERON calls it internal ear
  • UBERON:0009713 (2 mentions) - the report calls it "vestibular ganglion"; UBERON calls it endocardium of left ventricle

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • HP:0007141 (1 mention) - the report calls it "Sensory neuropathy"; HP calls it Sensorimotor neuropathy
  • UBERON:0000941 (2 mentions) - the report calls it "optic nerve"; UBERON calls it cranial nerve II, and lists "optic nerve" among its other names
  • CHEBI:2972 (2 mentions) - the report calls it "baclofen", "Pharmacologic: baclofen"; CHEBI calls it baclofen**, and lists "DL-Baclofen" among its other names
  • HP:0001417 (1 mention) - the report calls it "X-linked recessive inheritance"; HP calls it X-linked inheritance

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • CHEBI:2972 - called "baclofen", "Pharmacologic: **baclofen"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, OMIM.